# Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study.

<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-id journal-id-type="iso-abbrev">BMC Med</journal-id><journal-title-group><journal-title>BMC Medicine</journal-title></journal-title-group><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmcid">12403418</article-id><article-id pub-id-type="publisher-id">4352</article-id><article-id pub-id-type="doi">10.1186/s12916-025-04352-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Ma</surname><given-names>Delin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wei</surname><given-names>Pengcheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cheng</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Hao</surname><given-names>Jialing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Zuyin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Zhuomiaoyu</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Wenzai</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Zhigao</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Lo</surname><given-names>Chen</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Luo</surname><given-names>Yongjing</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Qiao</surname><given-names>Liyi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Gao</surname><given-names>Jie</given-names></name><address><email>gaojie_1131@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhu</surname><given-names>Jiye</given-names></name><address><email>gandanwk@vip.sina.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Li</surname><given-names>Zhao</given-names></name><address><email>lizhao@pku.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035adwg89</institution-id><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Department of Hepatobiliary Surgery, </institution><institution>Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035adwg89</institution-id><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Beijing Key Laboratory of HCC and Liver Cirrhosis, </institution><institution>Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035adwg89</institution-id><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Center of Liver Cancer Diagnosis and Treatment, </institution><institution>Peking University, Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/035adwg89</institution-id><institution-id institution-id-type="GRID">grid.411634.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0632 4559</institution-id><institution>Peking University Institute of Organ Transplantation, Peking University People&#x02019;s Hospital, </institution></institution-wrap>Beijing, China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03jxhcr96</institution-id><institution-id institution-id-type="GRID">grid.449412.e</institution-id><institution>Department of Hepatobiliary Surgery, </institution><institution>Peking University International Hospital, </institution></institution-wrap>Life Science Park of ZhongGuancun, Life Park Road No.1, Chang Ping District, Beijing, 102206 China </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04j1qx617</institution-id><institution-id institution-id-type="GRID">grid.459327.e</institution-id><institution>Department of General Surgery, </institution><institution>Civil Aviation General Hospital, </institution></institution-wrap>Beijing, 100123 China </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>23</volume><elocation-id>515</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>8</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Hepatocellular carcinoma (HCC) remains a major contributor to global cancer mortality, with liver transplantation (LT) offering curative potential for patients in the early stages. While immune checkpoint inhibitors (ICIs) are effective in managing tumor progression, concerns about graft rejection persist. This study investigates how peri-LT ICIs administration affects rejection rates and survival outcomes in HCC patients.</p></sec><sec><title>Methods</title><p id="Par2">This global study analyzed 386 HCC patients receiving Peri-LT ICIs therapy, integrating data from a systematic literature review and institutional registries. The risk of graft rejection and survival outcomes were assessed using logistic and Cox regression, along with restricted cubic splines modeling dose-response dynamics.</p></sec><sec><title>Results</title><p id="Par3">Overall graft rejection rates did not significantly differ between Pre-LT (17.5%) and Post-LT (22.1%) ICI users (<italic>P</italic> = 0.351); however, Post-LT use was associated with higher rates of graft loss/dysfunction (47.1% vs. 25.9%, <italic>P</italic> &#x0003c; 0.05) and rejection-related mortality (47.1% vs. 18.5%, <italic>P</italic> &#x0003c; 0.05). In Pre-LT patients, washout periods &#x0003e;30 days (OR = 0.36, 95% CI: 0.18&#x02013;0.72, <italic>P</italic> = 0.004) and &#x0003e;1.5 half-life counts (OR = 0.24, 95% CI: 0.12&#x02013;0.50, <italic>P</italic> &#x0003c; 0.001) were associated with reduced rejection risk. Post-LT, high PD-L1 expression on graft tissue correlated with increased rejection risk (<italic>P</italic> &#x0003c; 0.001). Graft rejection following Pre-LT ICIs was linked to poorer overall survival (HR = 5.17, 95% CI: 2.21&#x02013;12.24, <italic>P</italic> &#x0003c; 0.001).</p></sec><sec><title>Conclusions</title><p id="Par4">With careful management, peri-LT ICIs may be considered for HCC patients. Optimizing washout periods and monitoring graft PD-L1 expression may improve transplant outcomes.</p></sec><sec><title>Graphical Abstract</title><p id="Par5">
<graphic position="anchor" xlink:href="12916_2025_4352_Figa_HTML" id="MO1"/></p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12916-025-04352-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hepatocellular carcinoma</kwd><kwd>Liver transplantation</kwd><kwd>Immune checkpoint inhibitors</kwd><kwd>Graft rejection</kwd></kwd-group><funding-group><award-group><funding-source><institution>Capital Health Research and Development of Special Fund</institution></funding-source><award-id>2022-2-4084</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China</institution></funding-source><award-id>82472662</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Noncommunicable Chronic Diseases-National Science and Technology Major Project</institution></funding-source><award-id>2023ZD0502003</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par35">Liver cancer is a common and deadly malignancy worldwide, ranking sixth in incidence and fourth in cancer-related mortality [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Hepatocellular carcinoma (HCC) accounts for 75&#x02013;85% of primary liver cancers and continues to pose a significant global health threat due to its high incidence and mortality rates [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. For patients with early-stage HCC, liver transplantation (LT) presents a curative treatment option that also addresses underlying liver failure [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. However, the applicability of LT is limited, as most patients are diagnosed at intermediate or advanced stages and often experience disease progression during the waiting period, which results in lost transplant opportunities [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Effective tumor control strategies are urgently needed to enhance transplant accessibility and improve postoperative outcomes [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par36">Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy in oncology. By blocking PD-1/PD-L1 or CTLA-4 signaling pathways, ICIs boost antitumor immune responses and have demonstrated significant efficacy in advanced HCC [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Recent studies, such as the HIMALAYA trial, have confirmed the role of ICIs in systemic therapy for HCC, showing improved survival outcomes compared to traditional treatments [<xref ref-type="bibr" rid="CR16">16</xref>]. Within the context of LT, ICIs have been investigated as bridging or downstaging therapies to enhance transplant eligibility.</p><p id="Par37">The use of ICIs in the perioperative period of LT remains controversial [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Pre-LT ICIs may help control tumor progression and improve transplant eligibility, but concerns persist regarding post-transplant rejection, particularly if the washout period is insufficient [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. Furthermore, factors such as ICI type, treatment duration, and preoperative tumor burden may influence post-transplant outcomes [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Post-LT ICIs, once considered contraindicated due to the potential for heightened immune activation and graft rejection, are now being explored as salvage therapy for HCC recurrence after transplantation [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Despite these clinical implications, existing studies on Peri-LT ICIs use in HCC patients are limited, with most being retrospective analyses or case reports with small sample sizes. Systematic evaluations of the effects of Peri-LT ICIs administration on graft rejection and survival outcomes are urgently needed.</p><p id="Par38">In this study, we systematically evaluated the perioperative use of ICIs in HCC patients undergoing LT using clinical data from our center and a comprehensive literature review. We investigated whether pre-LT and post-LT ICI administration differ in graft rejection rates. Additionally, we explored risk factors associated with graft rejection and patient prognosis in both pre-LT and post-LT settings. Our findings aim to provide evidence-based Peri-LT ICIs strategies and optimize outcomes for HCC patients.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design</title><p id="Par39">This study aims to systematically evaluate the use of ICIs in HCC patients during the perioperative period of LT. Specifically, we focus on two key scenarios: Pre-LT ICIs use (administration before LT for downstaging or bridging) and Post-LT ICIs use (administration after LT for treating HCC recurrence). By aggregating and analyzing reported cases, we aim to assess differences in graft rejection rates between these two scenarios and evaluate the risk factors associated with graft rejection and patient prognosis. This study has been prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO) under the registration number CRD42025631304 to ensure methodological rigor and transparency.</p></sec><sec id="Sec4"><title>Literature search strategy</title><p id="Par40">We systematically searched English-language databases, including PubMed, Web of Science, Embase, and Scopus, as well as Chinese-language databases such as VIP, CNKI, Wanfang Database, and Sinomed, to collect relevant studies. Detailed search strategies and specific search strings are provided in Additional file 1: Text S1. The search period had no start date restrictions and concluded on December 31, 2024. No restrictions were imposed on publication type; conference abstracts were also considered. Reference lists of relevant reviews were manually screened to identify additional studies. A detailed flowchart of the literature search process is presented in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flowchart of literature screening and data extraction process</p></caption><graphic xlink:href="12916_2025_4352_Fig1_HTML" id="MO2"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Global and regional distribution and graft rejection differences. <bold>A</bold> World map showing geographical distribution of 386 cases with color-coded patient numbers. Pie charts indicate the proportion of ICIs administered Pre-LT (purple) versus Post-LT (gray). <bold>B</bold> Bar graph showing the number of patients by country. The bars are segmented to represent the proportion of patients receiving Pre-LT (light purple) and Post-LT (dark purple) ICIs. <bold>C</bold> Pie charts depicting the graft rejection rates for all patients (left), Pre-LT (middle), and Post-LT (right). <bold>D</bold> Bar graph comparing graft rejection rates between Pre-LT and Post-LT periods across the entire cohort</p></caption><graphic xlink:href="12916_2025_4352_Fig2_HTML" id="MO3"/></fig></p></sec><sec id="Sec5"><title>Literature screening process</title><p id="Par41">A systematic literature screening process was implemented to ensure the accuracy and completeness of the included studies (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>). All studies were imported into NoteExpress software and duplicates removed. Two independent reviewers (MDL and WPC) screened titles and abstracts to identify potentially eligible studies. Full-text articles were then retrieved for detailed assessment. To address duplicated case reporting, cases were compared by author names, affiliations, publication dates, and demographics (e.g., age, gender, diagnosis date). When duplication status was unclear, corresponding authors were contacted for clarification. Fully duplicated studies were excluded; partially duplicated cases were consolidated. Disagreements were resolved by discussion or adjudicated by a third reviewer (HJL).</p></sec><sec id="Sec6"><title>Quality assessment of literature</title><p id="Par42">To evaluate the quality of included studies, we used the Joanna Briggs Institute (JBI) Critical Appraisal Tools, an internationally recognized framework. These tools included specific checklists: eight questions for case reports, ten for case series, and eleven for cohort studies. Each checklist question was rated as <italic>Yes</italic>, <italic>No</italic>, or <italic>Unclear</italic>. Studies meeting &#x0003e;75% of the criteria were classified as high quality, those meeting between 50% and 75% as moderate quality, and &#x02264;50% as low quality. Detailed scoring criteria for the quality assessment are available in Additional file 2: Table S1.</p></sec><sec id="Sec7"><title>Data extraction from the literature</title><p id="Par43">We collected core variables for all included studies, such as study design, geographic origin, database language, and graft rejection outcomes. In studies involving Pre-LT ICIs, we gathered information on demographic profiles (age, gender, etiology), tumor characteristics (Milan criteria compliance, tumor multiplicity), ICIs-specific parameters (drug type, target, treatment cycles), and washout period metrics. A novel variable,"half-life counts,"was defined based on the elimination half-life values of ICIs from relevant pharmacological studies [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], calculated as: Washout period (days)/Drug-specific half-life (days). We recorded adjunctive therapies (surgery, radiotherapy, chemotherapy, locoregional therapy including TACE and local ablation, TKIs such as Sorafenib and Lenvatinib) and immunosuppressive regimens (Basiliximab, MMF, mTOR inhibitors, CNIs, corticosteroids), and data on tumor recurrence and patient mortality. For Post-LT ICIs studies, in addition to the core variables shared with Pre-LT cohorts (demographics, ICIs regimens, immunosuppressive protocols), we extracted Post-LT parameters, including time to recurrence, metastatic topography, and PD-L1 expression levels. PD-L1 expression was dichotomized using a staining proportion cut-off value of 20%, with samples showing &#x0003e;20% positive staining defined as high expression. Graft biopsies were performed to determine baseline graft PD-L1 expression levels, which were used to evaluate immunotherapy suitability. Additionally, graft loss was defined as patient death due to graft failure or the need for re-transplantation, in line with Banff and AASLD/EASL guidelines [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Graft dysfunction was defined as clinically significant impairment of graft function based on biochemical parameters (e.g., ALT/AST &#x02265;3&#x000d7;ULN, bilirubin elevation) and/or biopsy-proven rejection. Overall survival (OS) was defined as the time from LT to death from any cause for Pre-LT ICIs analyses, and as the time from tumor recurrence after LT to death for Post-LT ICIs analyses. Recurrence-free survival (RFS) was defined as the time from LT to HCC recurrence or death, whichever occurred first. Definitions were cross-checked for consistency across studies and adjusted if needed to ensure comparability. All variables were thoroughly annotated with missing data proportions (NA% per parameter) to ensure transparency and methodological rigor.</p></sec><sec id="Sec8"><title>Data collection at our center</title><p id="Par44">Clinical data for patients who underwent LT (June 2021&#x02013;December 2024) were collected via the electronic medical record system of Peking University People's Hospital. The inclusion criteria were as follows: (1) patients with a confirmed diagnosis of HCC who underwent LT; (2) patients who received at least one dose of ICI therapy either before or after surgery; and (3) patients with complete clinical data. The exclusion criteria included: (1) patients with other types of malignant tumors; (2) patients who underwent combined or multi-organ transplantation; and (3) patients with incomplete clinical data. For eligible patients, detailed variables were collected from the electronic records, and recurrence and survival information were obtained by telephone follow-up. All patient data were anonymized in accordance with ethical guidelines. The study protocol conforms to the ethical requirements of the Declaration of Helsinki and was approved by the Ethics Committee of Peking University People's Hospital.</p></sec><sec id="Sec9"><title>Statistical analysis</title><p id="Par45">Categorical variables were summarised as frequencies with percentages, while continuous variables were expressed as medians with interquartile ranges (IQR). For between-group comparisons, chi-square or Fisher&#x02019;s exact tests were used for categorical variables, depending on data characteristics. Continuous variables were analysed using t-tests or Mann-Whitney U tests based on distribution. Due to small sample size and multiple variables, Firth's penalised likelihood method was used for univariate and multivariate logistic regression to assess impacts on graft rejection. To explore potential nonlinear relationships between variables and the risk of graft rejection, restricted cubic spline analyses were conducted. Univariate Cox models with Firth's penalisation assessed risk factors for recurrence and mortality. Survival differences between groups were examined using Kaplan-Meier curves with log-rank tests. All analyses were two-sided, with statistical significance set at <italic>p </italic>&#x0003c; 0.05. All statistical analyses were carried out using R software (version 4.2.2).</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Literature screening and patient data extraction</title><p id="Par46">The literature search and screening process for this study is detailed in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. Initial searches identified 696 Chinese and 2,006 English articles, plus 8 from conference abstracts/references, totaling 2,710. After removing 895 duplicates, title/abstract screening excluded 1,567, and full-text review excluded another 165. Ultimately, 83 articles were eligible for data extraction. Of these, 77 cases were excluded for being non-HCC or duplicates. Finally, we gathered a cohort of 373 HCC patients with available graft rejection information, of whom 254 had relatively complete individual data. For transparency, the number of patients with relatively complete data and graft rejection information for each publication, together with the Web Link, is provided in Additional file 2: Table S1, while details on variable-specific missing data status (<italic>Complete, Completely missing, Partially missing</italic>) are summarized in Additional file 3: Dataset S1.</p></sec><sec id="Sec12"><title>Literature quality assessment</title><p id="Par47">A total of 83 studies were included: 46 case reports (55.4%), 32 case series (38.6%), and 5 cohort studies (6.0%), assessed using design-specific checklists. Case reports exhibited strong reporting quality, with 32 (69.5%) rated as high quality, 10 (21.7%) as moderate, and 4 (8.7%) as low. Key strengths included clear demographic descriptions (95.7% yes for Q1) and clinical timelines (93.5% yes for Q2). However, case reports demonstrated complete demographic/timeline reporting but had critical gaps in diagnostic documentation and adverse event tracking. Common limitations included inconsistent documentation of diagnostic methods (45.7% no for Q4) and adverse events (52.2% unclear/no for Q7). Case series (<italic>n&#x000a0;</italic>=32) exhibited moderate to high quality: 22 (68.8%) rated high, 7 (21.9%) moderate, and 3 (9.4%) low. Strengths included clear reporting of demographics, clinical information, and outcomes (&#x0003e;90.0% yes for Q6, Q7, and Q8), as well as statistical methods (96.9% yes for Q10). Here, &#x0201c;statistical methods&#x0201d; only referred to basic descriptive statistics, not advanced analytical designs. However, 43.8% of the case series lacked clear inclusion criteria (Q1), and 25.0% failed to ensure consecutive participant inclusion (Q4). Among five cohort studies, none were low quality; two (40%) were moderate due to insufficient follow-up information and inadequate handling of loss to follow-up (Q9, Q10). Overall, most studies (68.7%) across designs met high-quality thresholds, supporting methodological rigour for evidence synthesis. Detailed quality assessments are provided in Additional file 4: Table S2-4.</p></sec><sec id="Sec13"><title>Clinical characteristics of HCC patients with peri-LT ICIs use at our center</title><p id="Par48">Thirteen male patients were included after screening in our center, with a median age of 52 years (IQR: 50-55 years). All patients received ICIs prior to LT, with 84.6% (<italic>n</italic> = 11) of them using anti-PD-1 agents. Specifically, 38.5% (<italic>n</italic> = 5) of patients were treated with sintilimab, and 53.8% (<italic>n</italic> = 7) received ICIs as first-line therapy. The median number of ICI cycles administered was 2.5 (IQR: 2.0-4.0 cycles), and the median washout period between the final dose of ICIs and LT was 67 days (IQR: 35-154 days). Regarding non-ICI treatment measures, 61.5% (<italic>n</italic> = 8) of patients underwent surgery, 69.2% (<italic>n</italic> = 9) received TACE, and 76.9% (<italic>n</italic> = 10) were treated with TKIs, of which lenvatinib was used in 53.8% (<italic>n</italic> = 7) of cases. Notably, none of the patients experienced graft rejection following LT. During the follow-up period, 38.5% (<italic>n</italic> = 5) of patients experienced tumour recurrence, with a median recurrence-free survival time (RFS) of 270 days (IQR: 150-390 days). One patient (7.7%) died, and the median overall survival (OS) time was 270 days (IQR: 150-390 days). Detailed patient characteristics are provided in Additional file 5: Table S5. After integrating with literature cases, a cohort of 386 patients with graft rejection data and 267 with complete data was obtained.</p></sec><sec id="Sec14"><title>Global and regional distribution of included cases with peri-LT ICI Use</title><p id="Par49">This global cohort study analyzed 386 HCC cases related to Peri-LT ICI use, as indicated in&#x000a0;Fig. <xref rid="Fig2" ref-type="fig">2</xref>A and B and&#x000a0;Additional file 6: Table S6. The overall distribution of cases is as follows: 66.3% (<italic>n</italic> = 256) were from Asia, primarily from China, followed by the Americas (<italic>n</italic> = 96, 24.9%), Europe (<italic>n </italic>= 31, 8.0%), and Africa (<italic>n</italic> = 3, 0.8%). At the national level, China reported the highest number of cases (<italic>n</italic> = 235, 60.9%), while the USA had the second-highest (<italic>n</italic> = 93, 24.1%). In terms of literature sources, 79.0% (<italic>n</italic> = 305) of cases originated from English databases, 17.6% (<italic>n</italic> = 68) from Chinese databases, and 3.4% (<italic>n</italic> = 13) from unpublished studies. Regarding study type, cohort studies accounted for 45.3% (<italic>n</italic> = 175) of cases, case series constituted 43.3% (<italic>n</italic> = 167), and case reports made up 11.4% (<italic>n</italic> = 44).</p></sec><sec id="Sec15"><title>Graft rejection outcomes by ICIs treatment phase and subgroup analyses</title><p id="Par50">In terms of graft rejection, 71 cases (18.4%) experienced rejection, with 17.5% (<italic>n</italic> = 54) occurring in the Pre-LT ICIs group and 22.1% (<italic>n</italic> = 17) in the Post-LT ICIs group (Fig. <xref rid="Fig2" ref-type="fig">2</xref>C, Additional file 6: Table S6). Notably, there was no statistically significant difference in graft rejection rates between the two groups (Fig. <xref rid="Fig2" ref-type="fig">2</xref>D, <italic>P</italic> = 0.351). However, significant differences were observed in the distribution of ICI medication phases across variables, including country, region, and study type (all <italic>P</italic> &#x0003c; 0.001, Additional file 6: Table S6). For instance, Pre-LT ICIs usage was predominant in Asia (<italic>n</italic> = 219, 70.9%) and cohort studies (<italic>n</italic> = 175, 56.6%), while Post-LT usage was more common in Europe (<italic>n</italic> = 18, 23.4%) and case series studies (<italic>n</italic> = 59, 76.6%). Subgroup analyses showed no significant differences in graft rejection rates between Pre-LT and Post-LT ICIs groups across various countries, regions, literature sources, or study types (all <italic>P</italic>&#x0003e;0.05, Additional file 7: Figure S1 A-D).</p><p id="Par51">Further analysis of patients who experienced graft rejection revealed significant differences in rejection severity and mortality between the Pre-LT and Post-LT ICI groups. As shown in Fig. <xref rid="Fig3" ref-type="fig">3</xref>A, patients in the Post-LT group had a higher proportion of graft loss/dysfunction (<italic>n</italic> = 8, 47.1%) compared to the Pre-LT group (<italic>n</italic> = 14, 25.9%), while the proportion of complete recovery was significantly lower in the Post-LT group (<italic>n</italic> = 2, 11.8%) than in the Pre-LT group (<italic>n</italic> = 31, 57.4%). This indicates that graft rejection tends to be more severe in the Post-LT setting. Consistent with this finding, Fig. <xref rid="Fig3" ref-type="fig">3</xref>B demonstrates that the proportion of patients in whom graft rejection directly caused death was substantially higher in the Post-LT group (<italic>n</italic> = 8, 47.1%) compared to the Pre-LT group (<italic>n</italic> = 10, 18.5%).<fig id="Fig3"><label>Fig. 3</label><caption><p>Graft rejection outcomes in pre-LT/Post-LT ICI use and the relationship between washout period, half-life counts and graft rejection rate in pre-LT ICIs treatment HCC patients. <bold>A</bold>,&#x000a0;<bold>B</bold> The bar plots illustrate the differences in graft rejection severity (<bold>A</bold>) and death events caused by graft rejection (<bold>B</bold>) between Pre-LT and Post-LT use of ICIs, with results indicating significant differences (<italic>p </italic>&#x0003c; 0.05) in both aspects, showing higher severity and death rates in Post-LT cases. <bold>C</bold>,&#x000a0;<bold>D</bold> The bar plots present the differences in graft rejection between patients with washout periods of &#x02264;30 days versus &#x0003e;30 days (<bold>C</bold>) and half-life counts of &#x02264;1.5 versus &#x0003e;1.5 counts (<bold>D</bold>), both revealing significant associations (<italic>p </italic>&#x0003c; 0.05) between these factors and graft rejection risk</p></caption><graphic xlink:href="12916_2025_4352_Fig3_HTML" id="MO4"/></fig></p></sec><sec id="Sec16"><title>Clinical characteristics of HCC patients receiving pre-LT ICIs</title><p id="Par52">We examined patients who received ICIs before LT. This section includes a total of 204 patients with detailed records, as shown in Table <xref rid="Tab1" ref-type="table">1</xref>. The cohort comprised 131 patients (64.2%) aged &#x02264;60 years and 47 patients (23.0%) aged &#x0003e;60 years, with the majority being male (<italic>n</italic> = 158, 77.5%). HBV was the leading etiology (<italic>n</italic> = 95, 46.6%), followed by HCV (<italic>n</italic> = 19, 9.3%), ALD (<italic>n</italic> = 8, 3.9%), and MASH/MASLD (<italic>n</italic> = 8, 3.9%). Tumor characteristics showed that 21 (10.3%) patients met the Milan criteria, while 134 (64.2%) exceeded these criteria. Twenty-six (12.7%) presented with a single tumor, whereas 93 (45.6%) had multiple tumors. ICIs were administered to all patients, with anti-PD-1 therapy being the most common (<italic>n</italic> = 154, 75.5%), followed by anti-PD-L1 (<italic>n</italic> = 22, 10.8%) and combination therapies (<italic>n</italic> = 9, 4.5%). The distribution of ICI cycles among patients is as follows: 11.8% (<italic>n</italic> = 24) received 1 cycle, 59.3% (<italic>n</italic> = 121) received 2-10 cycles, and 18.1% (<italic>n</italic> = 37) received more than 10 cycles. The median washout period was 48 days (IQR: 22&#x02013;113 days), with 35.3% (<italic>n</italic> = 72) of patients experiencing a washout period of &#x02264;30 days. The median half-life count was 2 counts, with 27.0% (<italic>n</italic> = 55) having a half-life of &#x02264;1.5 counts. Other treatments included surgery (<italic>n</italic> = 38, 18.6%), radiotherapy (<italic>n</italic> = 6, 2.9%), chemotherapy (<italic>n</italic> = 19, 9.3%), and LRT (<italic>n</italic> = 145, 71.1%). TACE was performed in 56.9% (<italic>n</italic> = 116) of patients, local ablation in 15.7% (<italic>n</italic> = 144), and TKIs in 70.6% (<italic>n</italic> = 144). Immunosuppressive regimens included Basiliximab induction in 46.6% (<italic>n</italic> = 95) of patients, with maintenance immunosuppression consisting of MMF (<italic>n</italic> = 169, 82.8%), mTOR inhibitors (<italic>n</italic> = 82, 40.2%), CNIs (<italic>n</italic> = 179, 87.7%), and corticosteroids (<italic>n</italic> = 141, 69.1%).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics and graft rejection comparison in HCC patients receiving pre-LT ICIs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" rowspan="2">Overall<break/>(<italic>n</italic> = 204)</th><th align="left" colspan="2">Graft rejection</th><th align="left" rowspan="2"><italic>P</italic> value</th></tr><tr><th align="left">Yes (<italic>n</italic> = 44)</th><th align="left">No (<italic>n</italic> = 160)</th></tr></thead><tbody><tr><td align="left" colspan="4">Age, <italic>n</italic> (%)</td><td align="left">0.825</td></tr><tr><td align="left">&#x02003;&#x02266;60 years</td><td align="left">131 (64.2%)</td><td align="left">30 (68.2%)</td><td align="left">101 (63.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;60 years</td><td align="left">47 (23.0%)</td><td align="left">9 (20.5%)</td><td align="left">38 (23.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">26 (12.7%)</td><td align="left">5 (11.4%)</td><td align="left">21 (13.1%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Gender, <italic>n</italic> (%)</td><td align="left">0.761</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">20 (9.8%)</td><td align="left">4 (9.1%)</td><td align="left">16 (10.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Male</td><td align="left">158 (77.5%)</td><td align="left">36 (81.8%)</td><td align="left">122 (76.3%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">26 (12.7%)</td><td align="left">4 (9.1%)</td><td align="left">22 (13.8%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Etiology, <italic>n</italic> (%)</td><td align="left">0.135</td></tr><tr><td align="left">&#x02003;HBV</td><td align="left">95 (46.6%)</td><td align="left">15 (34.1%)</td><td align="left">80 (50.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;HCV</td><td align="left">19 (9.3%)</td><td align="left">6 (13.6%)</td><td align="left">13 (8.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;ALD</td><td align="left">8 (3.9%)</td><td align="left">3 (6.8%)</td><td align="left">5 (3.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;MASH/MASLD</td><td align="left">8 (3.9%)</td><td align="left">0 (0%)</td><td align="left">8 (5.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others<sup>a</sup></td><td align="left">13 (6.4%)</td><td align="left">3 (6.8%)</td><td align="left">10 (6.3%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">61 (29.9%)</td><td align="left">17 (38.6%)</td><td align="left">44 (27.5%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Milan criteria, <italic>n</italic> (%)</td><td align="left">0.066</td></tr><tr><td align="left">&#x02003;No</td><td align="left">134 (65.7%)</td><td align="left">26 (59.1%)</td><td align="left">108 (67.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Yes</td><td align="left">21 (10.3%)</td><td align="left">2 (4.5%)</td><td align="left">19 (11.9%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">49 (24.0%)</td><td align="left">16 (36.4%)</td><td align="left">33 (20.6%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Tumor number, <italic>n</italic> (%)</td><td align="left">0.446</td></tr><tr><td align="left">&#x02003;Single</td><td align="left">26 (12.7%)</td><td align="left">5 (11.4%)</td><td align="left">21 (13.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Multiple</td><td align="left">93 (45.6%)</td><td align="left">17 (38.6%)</td><td align="left">76 (47.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">85 (41.7%)</td><td align="left">22 (50.0%)</td><td align="left">63 (39.4%)</td><td align="left"/></tr><tr><td align="left" colspan="4">ICIs, <italic>n</italic> (%)</td><td align="left">0.048</td></tr><tr><td align="left">&#x02003;Atezolizumab</td><td align="left">21 (10.3%)</td><td align="left">0 (0%)</td><td align="left">21 (13.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Nivolumab</td><td align="left">41 (20.1%)</td><td align="left">9 (20.5%)</td><td align="left">32 (20.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Camrelizumab</td><td align="left">26 (12.7%)</td><td align="left">4 (9.1%)</td><td align="left">22 (13.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Pembrolizumab</td><td align="left">35 (17.2%)</td><td align="left">11 (25.0%)</td><td align="left">24 (15.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Sintilimab</td><td align="left">27 (13.2%)</td><td align="left">9 (20.5%)</td><td align="left">18 (11.3%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others<sup>b</sup></td><td align="left">34 (16.7%)</td><td align="left">9 (20.5%)</td><td align="left">25 (15.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">20 (9.8%)</td><td align="left">2 (4.5%)</td><td align="left">18 (11.3%)</td><td align="left"/></tr><tr><td align="left" colspan="4">ICIs target, <italic>n</italic> (%)</td><td align="left">0.013</td></tr><tr><td align="left">&#x02003;anti-PD-1</td><td align="left">154 (75.5%)</td><td align="left">41 (93.2%)</td><td align="left">113 (70.6%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-PD-L1</td><td align="left">22 (10.8%)</td><td align="left">0 (0%)</td><td align="left">22 (13.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-PD-1/anti-PD-L1</td><td align="left">5 (2.5%)</td><td align="left">1 (2.3%)</td><td align="left">4 (2.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-PD-1/anti-CTLA-4</td><td align="left">4 (2.0%)</td><td align="left">0 (0%)</td><td align="left">4 (2.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">19 (9.3%)</td><td align="left">2 (4.5%)</td><td align="left">17 (10.6%)</td><td align="left"/></tr><tr><td align="left">ICIs cycles, <italic>n</italic> (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.011</td></tr><tr><td align="left">&#x02003;1 cycle</td><td align="left">24 (11.8%)</td><td align="left">4 (9.1%)</td><td align="left">20 (12.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;1 cycle &#x00026; &#x02266;10 cycles</td><td align="left">121 (59.3%)</td><td align="left">21 (47.7%)</td><td align="left">100 (62.5%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;10 cycles</td><td align="left">37 (18.1%)</td><td align="left">8 (18.2%)</td><td align="left">29 (18.1%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">22 (10.8%)</td><td align="left">11 (25.0%)</td><td align="left">11 (6.9%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Washout period, days, Median (IQR)</td><td align="left">48 (22, 113)</td><td align="left">29 (16, 77)</td><td align="left">54 (28, 122)</td><td align="left">0.004</td></tr><tr><td align="left" colspan="4">Washout period, <italic>n</italic> (%)</td><td align="left">0.011</td></tr><tr><td align="left">&#x02003;&#x02266;30 days</td><td align="left">72 (35.3%)</td><td align="left">24 (54.5%)</td><td align="left">48 (30.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;30 days</td><td align="left">125 (61.3%)</td><td align="left">19 (43.2%)</td><td align="left">106 (66.3%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">7 (3.4%)</td><td align="left">1 (2.3%)</td><td align="left">6 (3.8%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Half-life counts<sup>c</sup>, <italic>n</italic>, Median (IQR)</td><td align="left">2 (1, 7)</td><td align="left">1 (1, 4)</td><td align="left">3 (2, 8)</td><td align="left">0.003</td></tr><tr><td align="left">Half-life counts, <italic>n</italic> (%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;&#x02266;1.5</td><td align="left">55 (27.0%)</td><td align="left">23 (52.3%)</td><td align="left">32 (20.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;1.5&#x02003;</td><td align="left">122 (59.8%)</td><td align="left">18 (40.9%)</td><td align="left">104 (65.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">27 (13.2%)</td><td align="left">3 (6.8%)</td><td align="left">24 (15.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Treatment measures excluding ICIs, <italic>n</italic> (%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Surgery</td><td align="left">38 (18.6%)</td><td align="left">6 (13.6%)</td><td align="left">32 (20.0%)</td><td align="left">0.036</td></tr><tr><td align="left">&#x02003;Radiotherapy</td><td align="left">6 (2.9%)</td><td align="left">2 (4.5%)</td><td align="left">4 (2.5%)</td><td align="left">0.076</td></tr><tr><td align="left">&#x02003;Chemotherapy</td><td align="left">19 (9.3%)</td><td align="left">4 (9.1%)</td><td align="left">15 (9.4%)</td><td align="left">0.055</td></tr><tr><td align="left">&#x02003;LRT</td><td align="left">145 (71.1%)</td><td align="left">37 (84.1%)</td><td align="left">108 (67.5%)</td><td align="left">0.006</td></tr><tr><td align="left">&#x02003;TACE</td><td align="left">116 (56.9%)</td><td align="left">30 (68.2%)</td><td align="left">86 (53.8%)</td><td align="left">0.184</td></tr><tr><td align="left">&#x02003;Local albationc</td><td align="left">32 (15.7%)</td><td align="left">6 (13.6%)</td><td align="left">26 (16.3%)</td><td align="left">0.915</td></tr><tr><td align="left">&#x02003;TKIs</td><td align="left">144 (70.6%)</td><td align="left">32 (72.7%)</td><td align="left">112 (70.0%)</td><td align="left">0.875</td></tr><tr><td align="left">&#x02003;Sorafenib</td><td align="left">20 (9.8%)</td><td align="left">7 (15.9%)</td><td align="left">13 (8.1%)</td><td align="left">0.281</td></tr><tr><td align="left">&#x02003;Lenvatinib</td><td align="left">121 (59.3%)</td><td align="left">29 (65.9%)</td><td align="left">92 (57.5%)</td><td align="left">0.514</td></tr><tr><td align="left">&#x02003;Bevacizumab</td><td align="left">24 (11.8%)</td><td align="left">1 (2.3%)</td><td align="left">23 (14.4%)</td><td align="left">0.076</td></tr><tr><td align="left" colspan="4">Immunosuppressive induction agents, <italic>n</italic> (%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Basiliximab</td><td align="left">95 (46.6%)</td><td align="left">28 (63.6%)</td><td align="left">67 (41.9%)</td><td align="left">0.026</td></tr><tr><td align="left" colspan="4">Immunosuppressive agents, <italic>n</italic> (%)</td><td align="left"/></tr><tr><td align="left">&#x02003;MMF</td><td align="left">169 (82.8%)</td><td align="left">37 (84.1%)</td><td align="left">132 (82.5%)</td><td align="left">0.732</td></tr><tr><td align="left">&#x02003;mTOR inhibitors</td><td align="left">82 (40.2%)</td><td align="left">22 (50.0%)</td><td align="left">60 (37.5%)</td><td align="left">0.208</td></tr><tr><td align="left">&#x02003;CNIs</td><td align="left">179 (87.7%)</td><td align="left">38 (86.4%)</td><td align="left">141 (88.1%)</td><td align="left">0.752</td></tr><tr><td align="left">&#x02003;Corticosteroids</td><td align="left">141 (69.1%)</td><td align="left">32 (72.7%)</td><td align="left">109 (68.1%)</td><td align="left">0.812</td></tr><tr><td align="left">Follow up data</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Recurrence after LT, <italic>n</italic> (%)</td><td align="left">41 (20.1%)</td><td align="left">4 (9.1%)</td><td align="left">37 (23.1%)</td><td align="left">0.090</td></tr><tr><td align="left">&#x02003;Recurrence-free survival time, days, Median (IQR)</td><td align="left">325 (120, 486)</td><td align="left">180 (39, 325)</td><td align="left">48 (22, 113)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;Death after LT, <italic>n</italic> (%)</td><td align="left">23 (11.3%)</td><td align="left">11 (25.0%)</td><td align="left">12 (7.5%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;Overall survival time, days, Median (IQR)</td><td align="left">328 (130, 570)</td><td align="left">48 (22, 113)</td><td align="left">48 (22, 113)</td><td align="left">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><p><italic>NA</italic> Not available, <italic>HBV</italic> Hepatitis B virus, <italic>HCV</italic> Hepatitis C virus, <italic>ALD</italic> Alcoholic liver disease, <italic>MASH/MASLD</italic> Metabolic dysfunction associated steatohepatitis/metabolic dysfunction-associate steatotic liver disease, <italic>ICIs</italic> Immune checkpoint inhibitors, <italic>PD-1</italic> Programmed cell death-1, <italic>PD-L1</italic> Programmed cell death-Ligand 1, <italic>CTLA-4</italic> Cytotoxic T lymphocyte-associated antigen-4, <italic>LRT</italic> Locoregional therapy, <italic>TACE</italic> Transcatheter arterial chemoembolization, <italic>TKIs</italic> Tyrosine kinase inhibitors, <italic>MMF</italic> Mycophenolate mofetil, <italic>mTOR</italic> Mammalian target of rapamycin, <italic>CNIs</italic> Calcineurin inhibitors, <italic>LT</italic> Liver transplantation</p><p><sup>a</sup>Others includes genetic causes, primary sclerosing cholangitis, multiple etiologies, and no identifiable etiology</p><p><sup>b</sup>Others includes Tislelizumab, Toripalimab, Penpilimab, Envafolimab, and combinations of multiple types of ICIs</p><p><sup>c</sup>Half-life counts were calculated as the washout period (days) divided by the half-life of the corresponding ICIs drug</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec17"><title>Risk factor analysis for graft rejection in HCC patients receiving pre-LT ICIs</title><p id="Par53">We investigated the differences between patients with graft rejection and those without among the 204 cases, as shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Of these, 44 experienced graft rejection and 160 did not. Significant differences were found in variables including ICIs (<italic>P</italic>=0.048), ICIs target (<italic>P</italic>=0.013), ICIs cycles (<italic>P</italic>=0.011), washout period (<italic>P</italic>=0.004 median; <italic>P</italic>=0.011 categorical), half-life counts (<italic>P</italic>=0.003 median; <italic>P</italic>&#x0003c;0.001 categorical), other treatments (surgery: <italic>P</italic>=0.036; LRT: <italic>P</italic>=0.006), and Basiliximab (<italic>P</italic>=0.026). Patients with a washout period &#x02264;30 days had a 33.3% rejection rate, versus 15.2% for &#x0003e;30 days. Those with &#x02264;1.5 half-life counts had a 41.8% rejection rate, versus 14.8% for &#x0003e;1.5 counts. These are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C and D.</p><p id="Par54">For washout period, a duration &#x0003e;30 days was linked to a lower risk of graft rejection (OR=0.36, 95% CI: 0.18&#x02013;0.72, <italic>P</italic>=0.004), consistent across models: Model 1 OR=0.35 (95% CI: 0.17-0.70, <italic>P</italic>=0.003), Model 2 OR=0.38 (95% CI: 0.18-0.78, <italic>P</italic>=0.008), Model 3 OR=0.40 (95% CI: 0.18-0.86, <italic>P</italic>=0.019), Model 4 OR=0.37 (95% CI: 0.17-0.77, <italic>P</italic>=0.008), and Model 5 OR=0.36 (95% CI: 0.17-0.75, <italic>P</italic>=0.006); Model 6 showed marginal significance (OR=0.42, 95% CI: 0.16-1.11, <italic>P</italic>=0.071). See Fig. <xref rid="Fig4" ref-type="fig">4</xref>A.<fig id="Fig4"><label>Fig. 4</label><caption><p>Multi-model validation and nonlinear relationships of washout period and half-life counts with graft rejection risk in pre-LT ICIs treatment HCC patients. <bold>A</bold>,&#x000a0;<bold>B</bold> Association between ICIs washout period (<bold>A</bold>), half-life counts (<bold>B</bold>), and the risk of graft rejection across various adjustment models. The reference groups were a washout period of &#x02264;30 days and half-life counts of &#x02264;1.5. Models were adjusted as follows: Model 1 included <italic>age</italic> and <italic>gender</italic>; Model 2 added <italic>etiology</italic>, <italic>tumor number</italic>, and <italic>Milan criteria</italic> to Model 1; Model 3 included <italic>ICIs type</italic>, <italic>target</italic>, and <italic>cycles</italic> in addition to Model 1; Model 4 incorporated <italic>surgery</italic>, <italic>radiotherapy</italic>, <italic>chemotherapy</italic>, <italic>LRT</italic>, <italic>TKIs</italic>, and <italic>bevacizumab</italic> into Model 1; Model 5 added <italic>basiliximab</italic>, <italic>MMF</italic>, <italic>mTOR inhibitors</italic>, and <italic>corticosteroids</italic> to Model 1; and Model 6 combined all the variables from Models 1-5. (<bold>C</bold>,&#x000a0;<bold>D</bold>) Dose-response relationships were evaluated using restricted cubic spline analyses for the washout period (days) (<bold>C</bold>) and half-life counts (<italic>n</italic>) (<bold>D</bold>), demonstrating unadjusted models (upper panels) and models adjusted for <italic>age</italic> and <italic>gender</italic> (lower panels)</p></caption><graphic xlink:href="12916_2025_4352_Fig4_HTML" id="MO5"/></fig></p><p id="Par55">Similarly, half-life counts &#x0003e;1.5 were linked to lower rejection risk (OR=0.24, 95% CI: 0.12-0.50, <italic>P</italic>&#x0003c;0.001), confirmed across all models: Model 1 OR=0.22 (95% CI: 0.10-0.47, <italic>P</italic>&#x0003c;0.001), Model 2 OR=0.21 (95% CI: 0.09-0.46, <italic>P</italic>&#x0003c;0.001), Model 3 OR=0.26 (95% CI: 0.11-0.60, <italic>P</italic>=0.001), Model 4 OR=0.19 (95% CI: 0.08-0.43, <italic>P</italic>&#x0003c;0.001), Model 5 OR=0.21 (95% CI: 0.09-0.47, <italic>P</italic>&#x0003c;0.001), and Model 6 OR=0.26 (95% CI: 0.08-0.72, <italic>P</italic>=0.010). See Fig. <xref rid="Fig4" ref-type="fig">4</xref>B.</p><p id="Par56">The subgroup analysis (Additional file 8: Figure S2) showed consistent trends: longer washout periods (&#x0003e;30 days) and higher half-life counts (&#x0003e;1.5) were generally linked to lower rejection risk across age, gender, etiology, and other subgroups. Restricted cubic spline analyses further explored dose-response relationships (Fig. <xref rid="Fig4" ref-type="fig">4</xref>C&#x02013;D). The unadjusted analyses showed significant overall associations for washout period (<italic>P</italic>=0.027) and half-life counts (<italic>P</italic>=0.040) with no evidence of nonlinearity. After adjustment for age and gender, overall associations remained (<italic>P</italic>=0.037 and <italic>P</italic>=0.044), still showing no nonlinearity (all <italic>P</italic>&#x0003e;0.2).</p></sec><sec id="Sec18"><title>Prognostic factors affecting RFS and OS in HCC patients receiving pre-LT ICI Treatment</title><p id="Par57">This study examined prognostic factors influencing RFS and OS in 204 patients who underwent Pre-LT ICIs Treatment. The median follow-up time for these patients was 325 days (IQR: 120-486 days). Forty-one patients (20.1%) experienced recurrence after LT, with a median RFS of 325 days (IQR: 22&#x02013;113 days). Additionally, 23 patients (11.3%) died after LT, with a median OS of 48 days (IQR: 22&#x02013;113 days). These results are presented in Table <xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par58">Univariate Cox analysis identified several variables significantly associated with RFS and OS (see Additional file 9: Table S7). For RFS, radiotherapy (HR=2.51, 95% CI: 1.03&#x02013;5.38, <italic>P</italic>=0.043) and TACE (HR=2.97, 95% CI: 1.40&#x02013;7.16, <italic>P</italic>=0.004) were significant. Basiliximab use was also linked to increased recurrence risk (HR=2.17, 95% CI: 1.09&#x02013;4.50, <italic>P</italic>=0.028). For OS, corticosteroids (HR=12.17, 95% CI: 1.67&#x02013;1549.2, <italic>P</italic>=0.007) and graft rejection (HR=5.17, 95% CI: 2.21&#x02013;12.24, <italic>P</italic>&#x0003c;0.001) were significant predictors. Kaplan-Meier curves showed that graft rejection did not significantly impact RFS (Log-rank <italic>P</italic>=0.476, Additional file 10: Figure S3 A-B) but was associated with lower OS (72.6% vs. 94.2% at 1 year; 72.6% vs. 90.9% at 2 and 3 years; Log-rank <italic>P</italic>&#x0003c;0.001, Additional file 10: Figure S3 C-D).</p></sec><sec id="Sec19"><title>Clinical characteristics in recurrence HCC patients receiving post-LT ICIs</title><p id="Par59">The baseline characteristics of patients who experienced HCC recurrence after LT and were treated with ICIs are outlined below. This analysis included 63 patients with detailed data. The cohort was predominantly male, accounting for 73.0% (<italic>n </italic>= 46) of the patients. Regarding age distribution, 55.6% (<italic>n </italic>= 35) of the patients were aged &#x02264;60 years, while 33.3% (<italic>n </italic>= 21) were &#x0003e;60 years. HBV and HCV were the most common etiologies, constituting 12.7% (<italic>n </italic>= 8) and 19.0% (<italic>n </italic>= 12) of cases, respectively. ICIs were primarily administered as non-first-line treatment (<italic>n </italic>= 57, 90.5%). Anti-PD-1 agents were the most prevalent (<italic>n </italic>= 46, 73.0%), with nivolumab being the most frequently utilized (<italic>n </italic>= 29, 46.0%). Most patients (<italic>n </italic>= 25, 39.7%) received ICIs between 1 and 5 years after LT. Notably, PD-L1 expression on the graft was evaluated in a subset of patients, with low PD-L1 expression noted in 22.2% (<italic>n </italic>= 14) of cases and high PD-L1 expression in 6.3% (<italic>n </italic>= 4) of cases. Recurrence or metastasis was most commonly observed in the liver (<italic>n </italic>= 22, 34.9%) and lungs (<italic>n </italic>= 31, 49.2%). TKIs were administered to 71.4% (<italic>n </italic>= 45) of patients, with sorafenib being the most common (<italic>n </italic>= 33, 52.4%). Immunosuppressive agents were given to the majority of patients, with CNIs being the most frequently used (<italic>n </italic>= 46, 73.0%), followed by mTOR inhibitors (<italic>n </italic>= 28, 44.4%) and MMF (<italic>n </italic>= 24, 38.1%). During follow-up, 47.6% (<italic>n </italic>= 30) died after recurrence. The median OS time following recurrence was 566 days (IQR: 321-990 days).</p></sec><sec id="Sec20"><title>Analysis of risk factors for graft rejection in recurrence HCC patients receiving post-LT ICIs</title><p id="Par60">Among the 63 patients receiving ICIs after LT, 13 experienced graft rejection while 50 did not. As shown in Table <xref rid="Tab2" ref-type="table">2</xref>, when comparing patients with and without graft rejection, the two groups were similar across most characteristics, including demographics, etiology, ICI-related factors, HCC recurrence features, and immunosuppressive agent use, with no significant differences noted. However, a significant difference was found in graft PD-L1 expression (<italic>P</italic>&#x0003c;0.001, Fig. <xref rid="Fig5" ref-type="fig">5</xref>A). In the low PD-L1 group, graft rejection incidence was 0%; in the high PD-L1 group, it was 100%. Patients with low graft PD-L1 expression were significantly less likely to develop rejection than those with high expression (OR=0.19, 95% CI: 0.08&#x02013;0.43, <italic>P</italic>&#x0003c;0.001, Fig. <xref rid="Fig5" ref-type="fig">5</xref>B). This association remained significant across six multiple logistic regression models, adjusting for different confounding factors. As shown in Fig. <xref rid="Fig5" ref-type="fig">5</xref>B, the ORs and 95% CIs consistently indicated lower rejection risk with low PD-L1 expression, with all <italic>P </italic>values &#x0003c;0.05 (Fig. <xref rid="Fig5" ref-type="fig">5</xref>B). This consistency highlights graft PD-L1 expression as a robust predictor of rejection in this population.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Baseline Characteristics and Graft Rejection Comparison in HCC Recurrence Patients Receiving Post-LT ICIs</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Characteristics</th><th align="left" rowspan="2">Overall<break/>(<italic>n </italic>= 63)</th><th align="left" colspan="2">Graft rejection</th><th align="left" rowspan="2"><italic>P </italic>value</th></tr><tr><th align="left">Yes (<italic>n </italic>= 13)</th><th align="left">No (<italic>n </italic>= 50)</th></tr></thead><tbody><tr><td align="left" colspan="4">Age, <italic>n </italic>(%)</td><td align="left">0.542</td></tr><tr><td align="left">&#x02003;&#x02266;60 years</td><td align="left">35 (55.6%)</td><td align="left">6 (46.2%)</td><td align="left">29 (58.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;60 years</td><td align="left">21 (33.3%)</td><td align="left">6 (46.2%)</td><td align="left">15 (30.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">7 (11.1%)</td><td align="left">1 (7.7%)</td><td align="left">6 (12.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Gender, <italic>n </italic>(%)</td><td align="left">&#x0003e;0.999</td></tr><tr><td align="left">&#x02003;Female</td><td align="left">10 (15.9%)</td><td align="left">2 (15.4%)</td><td align="left">8 (16.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Male</td><td align="left">46 (73.0%)</td><td align="left">10 (76.9%)</td><td align="left">36 (72.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">7 (11.1%)</td><td align="left">1 (7.7%)</td><td align="left">6 (12.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Etiology, <italic>n </italic>(%)</td><td align="left">0.183</td></tr><tr><td align="left">&#x02003;HBV</td><td align="left">8 (12.7%)</td><td align="left">2 (15.4%)</td><td align="left">6 (12.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;HCV</td><td align="left">12 (19.0%)</td><td align="left">3 (23.1%)</td><td align="left">9 (18.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;ALD</td><td align="left">2 (3.2%)</td><td align="left">0 (0%)</td><td align="left">2 (4.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;MASH/MASLD</td><td align="left">2 (3.2%)</td><td align="left">1 (7.7%)</td><td align="left">1 (2.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others<sup>a</sup></td><td align="left">3 (4.8%)</td><td align="left">2 (15.4%)</td><td align="left">1 (2.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">36 (57.1%)</td><td align="left">5 (38.5%)</td><td align="left">31 (62.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">ICIs, <italic>n </italic>(%)</td><td align="left">0.183</td></tr><tr><td align="left">&#x02003;Atezolizumab</td><td align="left">13 (20.6%)</td><td align="left">1 (7.7%)</td><td align="left">12 (24.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Nivolumab</td><td align="left">29 (46.0%)</td><td align="left">9 (69.2%)</td><td align="left">20 (40.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Camrelizumab</td><td align="left">9 (14.3%)</td><td align="left">1 (7.7%)</td><td align="left">8 (16.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Others<sup>b</sup></td><td align="left">12(19.0%)</td><td align="left">2 (15.4%)</td><td align="left">10 (20.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">&#x02003;ICIs target, <italic>n </italic>(%)</td><td align="left">0.471</td></tr><tr><td align="left">&#x02003;anti-PD-1</td><td align="left">46 (73.0%)</td><td align="left">12 (92.3%)</td><td align="left">34 (68.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-PD-L1</td><td align="left">15 (23.8%)</td><td align="left">1 (7.7%)</td><td align="left">14 (28.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-PD-1/anti-PD-L1</td><td align="left">1 (1.6%)</td><td align="left">0 (0%)</td><td align="left">1 (2.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;anti-CTLA-4</td><td align="left">1 (1.6%)</td><td align="left">0 (0%)</td><td align="left">1 (2.0%)</td><td align="left"/></tr><tr><td align="left">Line of ICIs, <italic>n </italic>(%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.164</td></tr><tr><td align="left">&#x02003;Non first-line</td><td align="left">57 (90.5%)</td><td align="left">12 (92.3%)</td><td align="left">45 (90.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;First-line</td><td align="left">5 (7.9%)</td><td align="left">0 (0%)</td><td align="left">5 (10.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">1 (1.6%)</td><td align="left">1 (7.7%)</td><td align="left">0 (0%)</td><td align="left"/></tr><tr><td align="left">Time from LT to ICIs, <italic>n </italic>(%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.651</td></tr><tr><td align="left">&#x02003;&#x02266;1year</td><td align="left">5 (7.9%)</td><td align="left">2 (15.4%)</td><td align="left">3 (6.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;1 year &#x00026; &#x02266;5 years</td><td align="left">25 (39.7%)</td><td align="left">5 (38.5%)</td><td align="left">20 (40.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;5 years</td><td align="left">4 (6.3%)</td><td align="left">0 (0%)</td><td align="left">4 (8.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">29 (46.0%)</td><td align="left">6 (46.2%)</td><td align="left">23 (46.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Graft PD-L1 expression, <italic>n </italic>(%)</td><td align="left">&#x0003c;0.001</td></tr><tr><td align="left">&#x02003;Low PD-L1 expression</td><td align="left">14 (22.2%)</td><td align="left">0 (0%)</td><td align="left">14 (28.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;High PD-L1 expression</td><td align="left">4 (6.3%)</td><td align="left">4 (30.8%)</td><td align="left">0 (0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Not biopsied</td><td align="left">45 (71.4%)</td><td align="left">9 (69.2%)</td><td align="left">36 (72.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Recurrence or metastasis site, <italic>n </italic>(%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Liver</td><td align="left">22 (34.9%)</td><td align="left">3 (23.1%)</td><td align="left">19 (38.0%)</td><td align="left">0.459</td></tr><tr><td align="left">&#x02003;Lung</td><td align="left">31 (49.2%)</td><td align="left">8 (61.5%)</td><td align="left">23 (46.0%)</td><td align="left">0.718</td></tr><tr><td align="left">&#x02003;Peritoneum</td><td align="left">9 (14.3%)</td><td align="left">2 (15.4%)</td><td align="left">7 (14.0%)</td><td align="left">&#x0003e;0.999</td></tr><tr><td align="left">&#x02003;Lymph node</td><td align="left">8 (12.7%)</td><td align="left">2 (15.4%)</td><td align="left">6 (12.0%)</td><td align="left">&#x0003e;0.999</td></tr><tr><td align="left">&#x02003;Other sites<sup>c</sup></td><td align="left">13 (20.6%)</td><td align="left">0 (0%)</td><td align="left">13 (26.0%)</td><td align="left">0.077</td></tr><tr><td align="left">Time from LT to recurrence, <italic>n </italic>(%)</td><td align="left"/><td align="left"/><td align="left"/><td align="left">0.337</td></tr><tr><td align="left">&#x02003;&#x02266;1year</td><td align="left">23 (36.5%)</td><td align="left">4 (30.8%)</td><td align="left">19 (38.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;1 year &#x00026; &#x02266;5 years</td><td align="left">30 (47.6%)</td><td align="left">9 (69.2%)</td><td align="left">21 (42.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;5 years</td><td align="left">4 (6.3%)</td><td align="left">0 (0%)</td><td align="left">4 (8.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">6 (9.5%)</td><td align="left">0 (0%)</td><td align="left">6 (12.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Treatment measures excluding ICIs, <italic>n </italic>(%)</td><td align="left"/></tr><tr><td align="left">&#x02003;Surgery</td><td align="left">17 (27.0%)</td><td align="left">1 (7.7%)</td><td align="left">16 (32.0%)</td><td align="left">0.150</td></tr><tr><td align="left">&#x02003;Radiotherapy</td><td align="left">12 (19.0%)</td><td align="left">1 (7.7%)</td><td align="left">11 (22.0%)</td><td align="left">0.586</td></tr><tr><td align="left">&#x02003;Chemotherapy</td><td align="left">16 (25.4%)</td><td align="left">5 (38.5%)</td><td align="left">11 (22.0%)</td><td align="left">0.474</td></tr><tr><td align="left">&#x02003;LRT</td><td align="left">20 (31.7%)</td><td align="left">3 (23.1%)</td><td align="left">17 (34.0%)</td><td align="left">0.793</td></tr><tr><td align="left">&#x02003;TACE</td><td align="left">12 (19.0%)</td><td align="left">0 (0%)</td><td align="left">12 (24.0%)</td><td align="left">0.105</td></tr><tr><td align="left">&#x02003;Local albation</td><td align="left">10 (15.9%)</td><td align="left">2 (15.4%)</td><td align="left">8 (16.0%)</td><td align="left">&#x0003e;0.999</td></tr><tr><td align="left">&#x02003;TKIs</td><td align="left">45 (71.4%)</td><td align="left">10 (76.9%)</td><td align="left">35 (70.0%)</td><td align="left">0.741</td></tr><tr><td align="left">&#x02003;Sorafenib</td><td align="left">33 (52.4%)</td><td align="left">7 (53.8%)</td><td align="left">26 (52.0%)</td><td align="left">&#x0003e;0.999</td></tr><tr><td align="left">&#x02003;Bevacizumab</td><td align="left">14 (22.2%)</td><td align="left">2 (15.4%)</td><td align="left">12 (24.0%)</td><td align="left">0.877</td></tr><tr><td align="left" colspan="4">TKIs type used, n (%)</td><td align="left">0.544</td></tr><tr><td align="left">&#x02003;0 type</td><td align="left">18 (28.6%)</td><td align="left">3 (23.1%)</td><td align="left">15 (30.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;1 type</td><td align="left">24 (38.1%)</td><td align="left">7 (53.8%)</td><td align="left">17 (34.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;&#x0003e;1 type</td><td align="left">17 (27.0%)</td><td align="left">2 (15.4%)</td><td align="left">15 (30.0%)</td><td align="left"/></tr><tr><td align="left">&#x02003;NA</td><td align="left">4 (6.3%)</td><td align="left">1 (7.7%)</td><td align="left">3 (6.0%)</td><td align="left"/></tr><tr><td align="left" colspan="4">Immunosuppressive agents, <italic>n </italic>(%)</td><td align="left"/></tr><tr><td align="left">&#x02003;MMF</td><td align="left">24 (38.1%)</td><td align="left">4 (30.8%)</td><td align="left">20 (40.0%)</td><td align="left">0.891</td></tr><tr><td align="left">&#x02003;mTOR inhibitors</td><td align="left">28 (44.4%)</td><td align="left">7 (53.8%)</td><td align="left">21 (42.0%)</td><td align="left">0.798</td></tr><tr><td align="left">&#x02003;CNIs</td><td align="left">46 (73.0%)</td><td align="left">8 (61.5%)</td><td align="left">38 (76.0%)</td><td align="left">0.440</td></tr><tr><td align="left">Follow up data</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x02003;Death after recurrence, <italic>n </italic>(%)</td><td align="left">30 (47.6%)</td><td align="left">9 (69.2%)</td><td align="left">21 (42.0%)</td><td align="left">0.238</td></tr><tr><td align="left">&#x02003;Overall survival time after recurrence, days, Median (IQR)</td><td align="left">566 (321, 990)</td><td align="left">780 (480, 806)</td><td align="left">548 (275, 990)</td><td align="left">0.561</td></tr></tbody></table><table-wrap-foot><p><italic>NA</italic> Not available, <italic>HBV</italic> Hepatitis B virus, <italic>HCV</italic> Hepatitis C virus, <italic>ALD</italic> Alcoholic liver disease, <italic>MASH/MASLD</italic> Metabolic dysfunction associated steatohepatitis/metabolic dysfunction-associate steatotic liver disease, <italic>ICIs</italic> Immune checkpoint inhibitors, <italic>PD-1</italic> Programmed cell death-1, <italic>PD-L1</italic> Programmed cell death-Ligand 1, <italic>CTLA-4</italic> Cytotoxic T lymphocyte-associated antigen-4, <italic>LT</italic> Liver transplantation, <italic>LRT</italic> Locoregional therapy, <italic>TACE</italic> Transcatheter arterial chemoembolization, <italic>TKIs</italic> Tyrosine kinase inhibitors, <italic>MMF</italic> Mycophenolate mofetil, <italic>mTOR</italic> Mammalian target of rapamycin, <italic>CNIs</italic> Calcineurin inhibitors</p><p><sup>a</sup>Others includes genetic causes, primary sclerosing cholangitis, multiple etiologies, and no identifiable etiology</p><p><sup>b</sup>Others includes Durvalumab, Ipilimumab, Pembrolizumab, Toripalimab, and combinations of multiple types of ICIs</p><p><sup>c</sup>Other sites includes adrenal gland, diaphragm, pericardium, brain, bone, and other unspecified locations</p></table-wrap-foot></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>The Association between Graft PD-L1 Expression and Graft Rejection Rate, and the Impact of Graft Rejection on OS after Recurrence in HCC Patients Receiving Post-LT ICIs. <bold>A</bold> Bar chart comparing the proportion of graft rejection across different PD-L1 expression categories. <bold>B</bold> Forest plot displaying OR with 95% confidence intervals for graft rejection risk according to PD-L1 expression levels across different adjustment models. High PD-L1 expression served as the reference group. Low PD-L1 expression consistently demonstrated strong protective effects against graft rejection across all models (all <italic>p</italic> &#x0003c; 0.05). Models were adjusted as follows: Model 1 included <italic>age</italic> and <italic>gender</italic>; Model 2 adjusted for <italic>etiology</italic>; Model 3 included t<italic>ime from LT to ICIs</italic>; Model 4 included <italic>liver recurrence</italic> and <italic>time from LT to recurrence</italic>; Model 5 included <italic>TKIs</italic> and <italic>LRT</italic>; and Model 6 adjusted for <italic>MMF</italic> and <italic>mTOR inhibitors</italic>. <bold>C</bold>,&#x000a0;<bold>D</bold> Kaplan-Meier curve and corresponding survival probability table comparing OS after recurrence between patients with graft rejection and those without it</p></caption><graphic xlink:href="12916_2025_4352_Fig5_HTML" id="MO6"/></fig></p></sec><sec id="Sec21"><title>Risk factor analysis for OS in recurrence HCC patients receiving post-LT ICIs</title><p id="Par61">The analysis of OS following recurrence in HCC patients receiving Post-LT ICIs identified several potential risk factors, as detailed in Additional file 11: Table S8. Univariate Cox regression analysis indicated that MASH/MASLD etiology (HR = 13.56, 95% CI: 1.20&#x02013;98.78, <italic>P </italic>= 0.038), a treatment interval exceeding five years from LT to ICIs (HR = 0.06, 95% CI: 0.00&#x02013;0.80, <italic>P</italic> = 0.032), and TACE treatment (HR = 0.24, 95% CI: 0.03&#x02013;0.92, <italic>P </italic>= 0.035) serve as significant predictors of OS. Other variables, including age, gender, HBV/HCV etiology, ICIs type, and time from LT to ICIs, did not show significant associations with OS (<italic>P </italic>&#x0003e; 0.05 for all). Interestingly, even graft rejection, which has been associated with poorer OS in the Pre-LT ICIs group, did not exhibit a significant association. The Kaplan-Meier curves also revealed no statistically significant difference in OS between patients with and without graft rejection (77.8% vs. 75.3% at 1 year; 64.8% vs. 65.2% at 2 years; 0.0% vs. 54.3% at 3 years; Log-rank <italic>P </italic>= 0.143, Fig. <xref rid="Fig5" ref-type="fig">5</xref>C-D). Nonetheless, the curves suggested a possible trend toward reduced survival in the rejection group at later timepoints, which may reflect limited sample size.</p></sec></sec><sec id="Sec22"><title>Discussion</title><p id="Par62">ICIs have transformed HCC treatment and are now widely utilized as neoadjuvant and adjuvant therapies [<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR32">32</xref>]. While existing case studies and series suggest that ICIs may be effective in bridging and downstaging therapy before LT and in addressing HCC recurrence after LT, their application remains contentious due to concerns about graft rejection and other side effects in solid organ transplant recipients. This study systematically examines the perioperative use of ICIs in LT for HCC patients, providing critical insights into this complex area. The findings reveal that the use of Peri-LT ICIs does not significantly heighten the overall risk of graft rejection. However, notable differences were observed in the severity and mortality of rejection between the Pre-LT and Post-LT ICIs groups. Specifically, in the Pre-LT ICIs context, a washout period of over 30 days and half-life counts exceeding 1.5 are linked to a reduced risk of rejection. In the Post-LT ICIs scenario, high PD-L1 expression on the graft appears to be correlated with an increased risk of rejection. This association should be interpreted cautiously, as the study was observational and cannot establish causality without further mechanistic validation. Moreover, graft rejection in the Pre-LT ICIs context is associated with poorer OS, while Post-LT rejection does not significantly affect OS.</p><p id="Par63">Our study analyzed clinical data from 386 HCC patients receiving Peri-LT ICIs treatment, revealing an overall graft rejection rate of 18.4%. This rate, along with specific rates in the Pre-LT (17%) and Post-LT (22%) groups, aligns with the 10%&#x02212;30% range documented in prior literature [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. These findings suggest that ICIs should not be viewed as absolute contraindications in the transplantation setting when appropriate monitoring and management protocols are followed. Moreover, our research provides the first comparative analysis between these clinical scenarios, indicating no statistically significant difference in rejection rates despite the slightly higher percentage in the Post-LT group. Given the retrospective nature of our analysis, high-quality prospective studies are necessary to further validate these observations. More importantly, patients experiencing rejection in the Post-LT context faced substantially more severe outcomes, with significantly higher rates of graft loss/dysfunction and mortality compared to the Pre-LT group. These results underscore the need for heightened vigilance and more proactive management strategies when administering ICIs in the Post-LT setting.</p><p id="Par64">Research on Pre-LT ICI usage has increasingly focused on determining optimal washout periods. A systematic review and meta-analysis by Rezaee-Zavareh et al. (96 patients) recommended a minimum washout period of 90 days for patients aiming for a rejection risk of less than 20% [<xref ref-type="bibr" rid="CR22">22</xref>]. Moeckli et al.'s international study of 119 HCC patients showed a clear correlation: rejection rates decreased from 50.0% (0-30 days washout) to 26.0% (30-50 days), and further dropped to below 10% when the washout exceeded 50 days, which is comparable to standard transplant populations [<xref ref-type="bibr" rid="CR36">36</xref>]. Similarly, Guo et al.'s analysis of 83 patients from 13 Chinese centers identified a &#x02265;30-day washout as an independent protective factor against rejection [<xref ref-type="bibr" rid="CR37">37</xref>]. Our findings confirm that a washout period of &#x02264;30 days significantly increases rejection risk, with restricted cubic spline analysis revealing an inverse relationship between washout duration and rejection probability. Importantly, patients with &#x0003e;30-day washout periods exhibited a 15.2% rejection rate, falling within conventional clinical parameters (10%&#x02212;30%). While longer washouts reduce rejection risk, they may delay transplantation, risking disease progression and transplant ineligibility [<xref ref-type="bibr" rid="CR38">38</xref>]. These results support adopting a 30-day minimum washout as a practical clinical threshold that balances rejection risk with concerns about transplant timing. Beyond duration alone, our analysis uncovers critical pharmacokinetic factors that influence optimal washout strategies. ICIs demonstrate significant variability in half-lives&#x02014;camrelizumab's relatively short 5.5-day half-life sharply contrasts with atezolizumab's extended 27.0-day elimination period [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. This variability renders fixed-duration washout protocols scientifically questionable and suggests that half-life-based criteria would provide more personalized and effective preoperative discontinuation guidelines. Kuo et al. previously proposed that long-half-life ICIs (22-27 days), such as nivolumab, pembrolizumab, and atezolizumab, require washout periods of roughly 1.5 times their half-life (42 days) to prevent rejection [<xref ref-type="bibr" rid="CR39">39</xref>]. However, their conclusions are based on limited samples that primarily focused on long-half-life ICIs. Our cohort, which includes a larger sample and incorporates shorter-half-life ICIs like camrelizumab, indicates that &#x0003e;1.5 half-life counts consistently offer better protection compared to standard &#x0003e;30-day washout protocols. Therefore, for HCC patients anticipating LT, choosing ICIs with shorter half-lives may represent a more logical therapeutic strategy that minimizes both washout duration and rejection risk.</p><p id="Par65">The clinical application of Post-LT ICIs remains under-investigated. Kahramangil et al. reported 39 Post-LT ICIs cases, finding that 4 of 6 patients with positive PD-L1 expression experienced rejection. They suggested that PD-L1 expression predicts ICI-related graft rejection [<xref ref-type="bibr" rid="CR40">40</xref>]. However, their study broadly defined PD-L1 expression, encompassing the transplanted liver, recurrent tumors, and livers prior to LT, as well as including other tumor types. This broad definition may affect the accuracy and specificity of the results. Therefore, we refined the variable definition to focus on PD-L1 expression in the transplanted liver after LT. Our results showed that all four patients with high PD-L1 expression experienced rejection, while none of the 11 with low expression did. This underscores the importance of detecting graft PD-L1 expression for rejection prediction. Emerging evidence elucidates the multifaceted role of the PD-1/PD-L1 axis in maintaining hepatic allograft tolerance. Mechanistically, PD-L1 upregulation in graft-resident stellate cells and dendritic cells promotes the apoptosis of cytotoxic T lymphocytes, thereby preserving immune quiescence [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Building upon these mechanistic insights, we hypothesize that grafts with high PD-L1 expression may primarily rely on PD-1/PD-L1 signaling for tolerance maintenance. Moreover, PD-1/PD-L1 inhibitors might disrupt this balance in high PD-L1 expression grafts, while CTLA-4-targeted ICIs could represent a safer alternative for these patients.</p><p id="Par66">We also observed an interesting phenomenon: the use of PD-L1 inhibitors, such as atezolizumab, appears associated with a lower incidence of graft rejection. Specifically, among the 22 patients who received PD-L1-targeted therapy in the Pre-LT group, none experienced graft rejection. Similarly, in the Post-LT group, only one out of 15 patients who received PD-L1-targeted therapy experienced graft rejection. These findings suggest a potential safety advantage of PD-L1-targeted therapy in the Peri-LT settings. PD-1 and PD-L1 are ligand-receptor pairs, but their expression sites differ. PD-1 is primarily expressed on the surface of immune cells like T cells and B cells, while PD-L1 is expressed not only on tumor cells but also on antigen-presenting cells (such as dendritic cells and macrophages) [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. It is important to note that PD-1 has another ligand, PD-L2, in addition to PD-L1 [<xref ref-type="bibr" rid="CR46">46</xref>]. Therefore, the use of PD-1 inhibitors simultaneously blocks the interaction between PD-1 on T cells and PD-L1 and PD-L2 on other cells, increasing the risk of potential autoimmune reactions. In contrast, PD-L1 inhibitors mainly bind to PD-L1 on tumor cells and antigen-presenting cells, restoring T cell-mediated antitumor immune responses without affecting the physiological function of PD-L2. Previous reports have shown that compared to PD-1 inhibitors, PD-L1 inhibitors have a lower incidence of grade 3 or higher adverse events, which may relate to the preservation of the PD-L2 pathway by PD-L1 inhibitors, thereby reducing the occurrence of related adverse events [<xref ref-type="bibr" rid="CR47">47</xref>]. Furthermore, a meta-analysis encompassing 125 clinical studies evaluated the incidence of treatment-related adverse events associated with PD-1 and PD-L1 inhibitors. The data indicated that patients treated with PD-1 inhibitors had a higher incidence of grade 3 or higher adverse events compared to those treated with PD-L1 inhibitors [<xref ref-type="bibr" rid="CR48">48</xref>]. Collectively, these data indicate the potential superiority of PD-L1 inhibitors over PD-1 inhibitors in peri-LT scenarios, where minimizing immune dysregulation is critical. Further prospective studies are warranted to validate these findings and optimize ICI selection protocols for LT patients.</p><p id="Par67">Previous studies have indicated a potential association between recipient age and the risk of graft rejection in LT. Kueht et al. analyzed data from 42,508 adult recipients in the U.S. Organ Procurement and Transplantation Network (OPTN) database. They found an inverse relationship between age and the incidence of acute rejection within one year post-transplant. Recipients aged 18-25 had a significantly higher risk of rejection compared to those over 60 [<xref ref-type="bibr" rid="CR49">49</xref>]. Similarly, a single-center retrospective study of 110 liver transplant recipients reported that patients experiencing acute rejection were significantly younger than those who did not. Additionally, recipients under 46 years of age exhibited higher peripheral CD8&#x0207a; T cell counts postoperatively, suggesting greater immune activation in younger individuals [<xref ref-type="bibr" rid="CR50">50</xref>]. A 2024 review by De Simone et al. further noted an acute rejection incidence of approximately 9% in recipients aged 65 years or older, significantly lower than the 23% observed in the 18-34 age group [<xref ref-type="bibr" rid="CR51">51</xref>]. In our study, recipient age was considered a potential influencing factor; however, no statistically significant association with graft rejection was identified. This discrepancy may be attributed to several factors: the relatively small sample size may have limited statistical power; the narrow age distribution may have reduced detectable age-related immune variation; and standardized, intensified perioperative immunosuppression may have minimized age-dependent differences in immune activation.</p><p id="Par68">This study represents the largest cohort to date evaluating Peri-LT ICIs therapy in HCC patients. We are the first to outline the different safety profiles and therapeutic outcomes between Pre-LT and Post-LT ICI administration through systematic comparative analysis. Previous studies were limited to English-language databases, which may have led to case omission bias. To address this, we innovatively integrated both Chinese and English databases for comprehensive data collection. Given China's high incidence of HCC and distinct etiological patterns compared to Western populations, our cohort more accurately represents real-world data. This study has several limitations. First, most included studies were case reports or retrospective case series with small sample sizes, which may introduce publication bias. Second, the number of patients in the Post-LT ICIs group was relatively small, and relevant data remain limited. Third, there was considerable heterogeneity across studies in terms of ICIs types, treatment regimens, immunosuppressive strategies, and follow-up durations, as well as limited biopsy-based PD-L1 expression data, which limits the generalizability of the findings. Moving forward, large-scale, multicenter, and rigorously designed prospective studies should be conducted to determine individualized management strategies for HCC patients receiving Peri-LT ICIs therapy, as they are essential for enhancing the efficacy and safety of such therapies in this specific patient population.</p></sec><sec id="Sec23"><title>Conclusions</title><p id="Par69">This global cohort study systematically evaluated the safety and efficacy of ICIs therapy in HCC patients in the Peri-LT setting. The study found that while the overall risk of graft rejection with Peri-LT ICIs use appeared comparable to historical data from patients without ICIs exposure, the severity of rejection and mortality are significantly higher in patients receiving Post-LT ICIs. In the Pre-LT setting, a washout period of &#x0003e;30 days and half-life counts of &#x0003e;1.5 are associated with a reduced risk of graft rejection. Conversely, high PD-L1 expression on the graft is a significant risk factor for rejection in the Post-LT setting. Graft rejection in Pre-LT patients is associated with worse overall survival, while Post-LT rejection does not significantly impact overall survival. These findings provide critical insights for the clinical application of ICIs in the perioperative management of HCC patients undergoing LT. Optimizing the washout period and monitoring PD-L1 expression can enhance transplant outcomes.</p></sec><sec id="Sec24" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12916_2025_4352_MOESM1_ESM.docx"><caption><p>Additional file 1: Text S1. Detailed search strategies and search strings used in the literature search.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12916_2025_4352_MOESM2_ESM.docx"><caption><p>Additional file 2: Table S1. Summary of included publications with patient numbers and data sources.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12916_2025_4352_MOESM3_ESM.xlsx"><caption><p>Additional file 3: Dataset S1. Summary of variable-specific missing data status.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12916_2025_4352_MOESM4_ESM.docx"><caption><p>Additional file 4: Table S2-4. Table S2. Quality assessment checklist for case reports. Table S3. Quality assessment checklist for case series. Table S4. Quality assessment checklist for cohort studies.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="12916_2025_4352_MOESM5_ESM.docx"><caption><p>Additional file 5: Table S5. Baseline characteristics of 13 cases receiving Peri-LT ICIs in our center.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="12916_2025_4352_MOESM6_ESM.docx"><caption><p>Additional file 6: Table S6. Basic characteristics of included cases with Peri-LT ICIs use.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM7"><media xlink:href="12916_2025_4352_MOESM7_ESM.png"><caption><p>Additional file 7: Figure S1. Comparison of graft rejection rates among patients receiving Pre- or Post-LT ICIs across various subgroups. Bar charts comparing graft rejection rates in patients receiving ICIs Pre-LT versus Post-LT, stratified by: Country; Region; Study design; Data source.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM8"><media xlink:href="12916_2025_4352_MOESM8_ESM.png"><caption><p>Additional file 8: Figure S2. Subgroup analysis of relationships between washout period, half-life counts, and graft rejection risk across different characteristics in Pre-LT ICIs treatment HCC patients.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM9"><media xlink:href="12916_2025_4352_MOESM9_ESM.docx"><caption><p>Additional file 9: Table S7. Univariate Cox regression analysis of recurrence and survival in HCC patients receiving Pre-LT ICIs.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM10"><media xlink:href="12916_2025_4352_MOESM10_ESM.png"><caption><p>Additional file 10: Figure S3. Impact of graft rejection on RFS and OS following LT in HCC patients receiving Pre-LT ICIs. Kaplan-Meier curves and the corresponding tabular data for RFS comparing patients with graft rejection to those without graft rejection. Kaplan-Meier curves and the corresponding tabular data for OS comparing patients with graft rejection to those without graft rejection.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM11"><media xlink:href="12916_2025_4352_MOESM11_ESM.docx"><caption><p>Additional file 11: Table S8. Univariate Cox regression analysis of survival in HCC recurrence patients receiving Post-LT ICIs.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>HCC</term><def><p id="Par6">Hepatocellular carcinoma</p></def></def-item><def-item><term>HBV</term><def><p id="Par7">Hepatitis B virus</p></def></def-item><def-item><term>HCV</term><def><p id="Par8">Hepatitis C virus</p></def></def-item><def-item><term>ALD</term><def><p id="Par9">Alcoholic liver disease</p></def></def-item><def-item><term>MASH/MASLD</term><def><p id="Par10">Metabolic dysfunction associated steatohepatitis/metabolic dysfunction-associate steatotic liver disease</p></def></def-item><def-item><term>ICIs</term><def><p id="Par11">Immune checkpoint inhibitors</p></def></def-item><def-item><term>PD-1</term><def><p id="Par12">Programmed cell death-1</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par13">Programmed cell death-Ligand 1</p></def></def-item><def-item><term>CTLA-4</term><def><p id="Par14">Cytotoxic T lymphocyte-associated antigen-4</p></def></def-item><def-item><term>LRT</term><def><p id="Par15">Locoregional therapy</p></def></def-item><def-item><term>TACE</term><def><p id="Par16">Transcatheter arterial chemoembolization</p></def></def-item><def-item><term>TKIs</term><def><p id="Par17">Tyrosine kinase inhibitors</p></def></def-item><def-item><term>MMF</term><def><p id="Par18">Mycophenolate mofetil</p></def></def-item><def-item><term>mTOR</term><def><p id="Par19">Mammalian target of rapamycin</p></def></def-item><def-item><term>CNIs</term><def><p id="Par20">Calcineurin inhibitors</p></def></def-item><def-item><term>LT</term><def><p id="Par21">Liver transplantation</p></def></def-item><def-item><term>CI</term><def><p id="Par22">Confidence interval</p></def></def-item><def-item><term>Cox</term><def><p id="Par23">Cox proportional hazards model</p></def></def-item><def-item><term>HR</term><def><p id="Par24">Hazard ratio</p></def></def-item><def-item><term>IQR</term><def><p id="Par25">Interquartile ranges</p></def></def-item><def-item><term>JBI</term><def><p id="Par26">Joanna Briggs Institute</p></def></def-item><def-item><term>LT</term><def><p id="Par27">Liver transplantation</p></def></def-item><def-item><term>NA</term><def><p id="Par28">Not available</p></def></def-item><def-item><term>OR</term><def><p id="Par29">Odds ratio</p></def></def-item><def-item><term>OS</term><def><p id="Par30">Overall survival</p></def></def-item><def-item><term>RFS</term><def><p id="Par31">Recurrence-free survival</p></def></def-item><def-item><term>PD-L2</term><def><p id="Par32">Programmed death ligand 2</p></def></def-item><def-item><term>RCS</term><def><p id="Par33">Restricted cubic spline</p></def></def-item><def-item><term>OPTN</term><def><p id="Par34">Organ procurement and transplantation network</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Delin Ma, Pengcheng Wei and Qian Cheng contributed equally to this work as co-first authors.</p></fn></fn-group><ack><p>We sincerely express our gratitude to all participants, collaborators, and institutions involved in this research for their valuable support and contributions, which have greatly facilitated the completion of this work.</p></ack><notes notes-type="author-contribution"><title>Authors' contributions</title><p>D.M., P.W., Q.C., J.G., J.Z., and ZL2 designed the study. D.M., J.H., and ZL1 developed the methodology. D.M., P.W., J.H., and Z.C. collected the data. D.M., P.W., and ZL1 analyzed and interpreted the results. P.W., J.H., W.S., Z.Y., C.L., Y.L., L.Q., and J.G. provided technical and material support. J.G. and J.Z. supervised the study. D.M., P.W., Q.C., J.G., J.Z., and ZL2 drafted and reviewed the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The research was funded by the Capital Health Research and Development of Special Fund (2022-2-4084), the National Natural Science Foundation of China (Grant No. 82472662), and the Noncommunicable Chronic Diseases-National Science and Technology Major Project (Project No. 2023ZD0502003).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data supporting this study's findings are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par70">This study was approved by the Ethics Committee of Peking University People&#x02019;s Hospital (Approval No. 2025PHB229-001). All methods were carried out in accordance with relevant guidelines and regulations.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par71">All authors have agreed to the submission and publication of this research.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par72">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Lampertico</surname><given-names>P</given-names></name><name><surname>Nahon</surname><given-names>P</given-names></name></person-group><article-title>Epidemiology and surveillance for hepatocellular carcinoma: New trends</article-title><source>J Hepatol.</source><year>2020</year><volume>72</volume><issue>2</issue><fpage>250</fpage><lpage>61</lpage><?supplied-pmid 31954490?><pub-id pub-id-type="pmid">31954490</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. J Hepatol. 2020;72(2):250&#x02013;61.<pub-id pub-id-type="pmid">31954490</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Elena P, Ariana MC, Bryar H, Eduardo AV, Claudius C. Robotic <italic>vs.</italic> laparoscopic resection for hepatocellular carcinoma. Mini-invasive Surgery. 2023;7:13.</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Kanwal</surname><given-names>F</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy</article-title><source>Nat Rev Clin Oncol.</source><year>2023</year><volume>20</volume><issue>12</issue><fpage>864</fpage><lpage>84</lpage><?supplied-pmid 37884736?><pub-id pub-id-type="pmid">37884736</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20(12):864&#x02013;84.<pub-id pub-id-type="pmid">37884736</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy</article-title><source>MedComm&#x000a0;(2020)</source><year>2024</year><volume>5</volume><issue>2</issue><fpage>e474</fpage><?supplied-pmid 38318160?><pub-id pub-id-type="pmid">38318160</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Luo X, He X, Zhang X, Zhao X, Zhang Y, Shi Y, et al. Hepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy. MedComm&#x000a0;(2020). 2024;5(2):e474.<pub-id pub-id-type="pmid">38318160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Gianluca</surname><given-names>C</given-names></name><name><surname>Ho-Seong</surname><given-names>H</given-names></name><name><surname>Boram</surname><given-names>L</given-names></name><name><surname>Hae-Won</surname><given-names>L</given-names></name><name><surname>Jai Young</surname><given-names>C</given-names></name><name><surname>Roberto</surname><given-names>Ivan T</given-names></name></person-group><article-title>Minimally-invasive anatomical liver resection for hepatocellular carcinoma: a literature overview with technical and anatomical tips and tricks</article-title><source>Mini-invasive Surgery.</source><year>2023</year><volume>7</volume><fpage>5</fpage></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Gianluca C, Ho-Seong H, Boram L, Hae-Won L, Jai Young C, Roberto Ivan T. Minimally-invasive anatomical liver resection for hepatocellular carcinoma: a literature overview with technical and anatomical tips and tricks. Mini-invasive Surgery. 2023;7:5.</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Pinyol</surname><given-names>R</given-names></name><name><surname>Yarchoan</surname><given-names>M</given-names></name><name><surname>Singal</surname><given-names>AG</given-names></name><name><surname>Marron</surname><given-names>TU</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma</article-title><source>Nat Rev Clin Oncol.</source><year>2024</year><volume>21</volume><issue>4</issue><fpage>294</fpage><lpage>311</lpage><?supplied-pmid 38424197?><pub-id pub-id-type="pmid">38424197</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, et al. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024;21(4):294&#x02013;311.<pub-id pub-id-type="pmid">38424197</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Bhoori</surname><given-names>S</given-names></name><name><surname>Mehta</surname><given-names>N</given-names></name><name><surname>Mazzaferro</surname><given-names>V</given-names></name></person-group><article-title>Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation</article-title><source>J Hepatol.</source><year>2024</year><volume>81</volume><issue>4</issue><fpage>743</fpage><lpage>55</lpage><?supplied-pmid 38848767?><pub-id pub-id-type="pmid">38848767</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Li M, Bhoori S, Mehta N, Mazzaferro V. Immunotherapy for hepatocellular carcinoma: The next evolution in expanding access to liver transplantation. J Hepatol. 2024;81(4):743&#x02013;55.<pub-id pub-id-type="pmid">38848767</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Norman</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>PJ</given-names></name><name><surname>Kotwani</surname><given-names>P</given-names></name><name><surname>Shui</surname><given-names>AM</given-names></name><name><surname>Yao</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>N</given-names></name></person-group><article-title>AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation</article-title><source>J Hepatol.</source><year>2023</year><volume>79</volume><issue>6</issue><fpage>1469</fpage><lpage>77</lpage><?supplied-pmid 37683735?><pub-id pub-id-type="pmid">37683735</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Norman JS, Li PJ, Kotwani P, Shui AM, Yao F, Mehta N. AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation. J Hepatol. 2023;79(6):1469&#x02013;77.<pub-id pub-id-type="pmid">37683735</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">van der Meeren PE, de Wilde RF, Sprengers D, IJzermans JNM. Benefit and harm of waiting time in liver transplantation for HCC. Hepatology. 2025;82(1):212&#x02013;231.</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y-K</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>Y-S</given-names></name><name><surname>Zhang</surname><given-names>W-H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y-H</given-names></name><etal/></person-group><article-title>Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study</article-title><source>J Hepatocell Carcinoma.</source><year>2024</year><volume>11</volume><fpage>1389</fpage><lpage>402</lpage><?supplied-pmid 39011125?><pub-id pub-id-type="pmid">39011125</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Li Y-K, Wu S, Wu Y-S, Zhang W-H, Wang Y, Li Y-H, et al. Portal Venous and Hepatic Arterial Coefficients Predict Post-Hepatectomy Overall and Recurrence-Free Survival in Patients with Hepatocellular Carcinoma: A Retrospective Study. J Hepatocell Carcinoma. 2024;11:1389&#x02013;402.<pub-id pub-id-type="pmid">39011125</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y-B</given-names></name><name><surname>Wang</surname><given-names>Q-B</given-names></name><name><surname>Li</surname><given-names>Y-K</given-names></name><name><surname>Chen</surname><given-names>X-M</given-names></name><name><surname>Luo</surname><given-names>W-L</given-names></name><etal/></person-group><article-title>Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis</article-title><source>Front Immunol.</source><year>2024</year><volume>15</volume><fpage>1519999</fpage><?supplied-pmid 39840048?><pub-id pub-id-type="pmid">39840048</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Li J, Liang Y-B, Wang Q-B, Li Y-K, Chen X-M, Luo W-L, et al. Tumor-associated lymphatic vessel density is a postoperative prognostic biomarker of hepatobiliary cancers: a systematic review and meta-analysis. Front Immunol. 2024;15:1519999.<pub-id pub-id-type="pmid">39840048</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q-B</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z-J</given-names></name><name><surname>Li</surname><given-names>Y-K</given-names></name><name><surname>Liang</surname><given-names>Y-B</given-names></name><name><surname>Chen</surname><given-names>X-M</given-names></name><etal/></person-group><article-title>The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysis</article-title><source>Expert Rev Anticancer Ther.</source><year>2025</year><volume>25</volume><issue>5</issue><fpage>561</fpage><lpage>70</lpage><?supplied-pmid 40181594?><pub-id pub-id-type="pmid">40181594</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wang Q-B, Li J, Zhang Z-J, Li Y-K, Liang Y-B, Chen X-M, et al. The effectiveness and safety of therapies for hepatocellular carcinoma with tumor thrombus in the hepatic vein, inferior vena cave and/or right atrium: a systematic review and single-arm meta-analysis. Expert Rev Anticancer Ther. 2025;25(5):561&#x02013;70.<pub-id pub-id-type="pmid">40181594</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy</article-title><source>Front Immunol.</source><year>2022</year><volume>13</volume><fpage>1070961</fpage><?supplied-pmid 36601120?><pub-id pub-id-type="pmid">36601120</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.<pub-id pub-id-type="pmid">36601120</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma</article-title><source>Front Immunol.</source><year>2021</year><volume>12</volume><fpage>783236</fpage><?supplied-pmid 34899747?><pub-id pub-id-type="pmid">34899747</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Xing R, Gao J, Cui Q, Wang Q. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma. Front Immunol. 2021;12: 783236.<pub-id pub-id-type="pmid">34899747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhong</surname><given-names>A</given-names></name><name><surname>Min</surname><given-names>J</given-names></name><name><surname>Tu</surname><given-names>H</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment</article-title><source>ACS Appl Mater Interfaces.</source><year>2024</year><volume>16</volume><issue>6</issue><fpage>6894</fpage><lpage>907</lpage><?supplied-pmid 38306190?><pub-id pub-id-type="pmid">38306190</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Zhang Y, Zhong A, Min J, Tu H, Cao Y, Fu J, et al. Biomimetic Responsive Nanoconverters with Immune Checkpoint Blockade Plus Antiangiogenesis for Advanced Hepatocellular Carcinoma Treatment. ACS Appl Mater Interfaces. 2024;16(6):6894&#x02013;907.<pub-id pub-id-type="pmid">38306190</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Abou-Alfa</surname><given-names>GK</given-names></name><name><surname>Lau</surname><given-names>G</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Chan</surname><given-names>SL</given-names></name><name><surname>Kelley</surname><given-names>RK</given-names></name><name><surname>Furuse</surname><given-names>J</given-names></name><etal/></person-group><article-title>Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)</article-title><source>Future Oncol.</source><year>2023</year><volume>19</volume><issue>38</issue><fpage>2505</fpage><lpage>16</lpage><?supplied-pmid 37671641?><pub-id pub-id-type="pmid">37671641</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol. 2023;19(38):2505&#x02013;16.<pub-id pub-id-type="pmid">37671641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Tabrizian</surname><given-names>P</given-names></name><name><surname>Marino</surname><given-names>R</given-names></name><name><surname>Chow</surname><given-names>PKH</given-names></name></person-group><article-title>Liver resection and transplantation in the era of checkpoint inhibitors</article-title><source>JHEP Rep.</source><year>2024</year><volume>6</volume><issue>11</issue><fpage>101181</fpage><?supplied-pmid 39741696?><pub-id pub-id-type="pmid">39741696</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Tabrizian P, Marino R, Chow PKH. Liver resection and transplantation in the era of checkpoint inhibitors. JHEP Rep. 2024;6(11): 101181.<pub-id pub-id-type="pmid">39741696</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group><article-title>Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma</article-title><source>Chin Med J (Engl).</source><year>2024</year><volume>137</volume><issue>18</issue><fpage>2143</fpage><lpage>5</lpage><?supplied-pmid 39148191?><pub-id pub-id-type="pmid">39148191</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Wang Z, Yang J, Li G. Chinese expert consensus on the application of immune checkpoint inhibitors in liver transplantation for hepatocellular carcinoma. Chin Med J (Engl). 2024;137(18):2143&#x02013;5.<pub-id pub-id-type="pmid">39148191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Anugwom CM, Leventhal TM, Debes JD. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Hepatoma Res. 2022;8:7.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Marzi L, Mega A, Turri C, Gitto S, Ferro F, Spizzo G. Immune Checkpoint Inhibitors in the Pre-Transplant Hepatocellular Carcinoma Setting: A Glimpse Beyond the Liver. Int J Mol Sci. 2024;25(21):11676.</mixed-citation></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>Y</given-names></name><name><surname>Tilak</surname><given-names>B</given-names></name><name><surname>Aiwu Ruth</surname><given-names>H</given-names></name><name><surname>Coleman</surname><given-names>S</given-names></name></person-group><article-title>Immune checkpoint inhibitors in liver transplant recipients - a review of current literature</article-title><source>Hepatoma Research.</source><year>2021</year><volume>7</volume><fpage>52</fpage></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Chao Y, Tilak B, Aiwu Ruth H, Coleman S. Immune checkpoint inhibitors in liver transplant recipients - a review of current literature. Hepatoma Research. 2021;7:52.</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Rezaee-Zavareh</surname><given-names>MS</given-names></name><name><surname>Yeo</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Tabrizian</surname><given-names>P</given-names></name><name><surname>Ward</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis</article-title><source>J Hepatol.</source><year>2025</year><volume>82</volume><issue>1</issue><fpage>107</fpage><lpage>19</lpage><?supplied-pmid 38996924?><pub-id pub-id-type="pmid">38996924</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 2025;82(1):107&#x02013;19.<pub-id pub-id-type="pmid">38996924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel). 2021;13(24):6307.</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Abboud K, Umoru G, Esmail A, Abudayyeh A, Murakami N, Al-Shamsi HO, et al. Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. Cancers (Basel). 2023;15(5):1433.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Wassmer CH, El Hajji S, Papazarkadas X, Compagnon P, Tabrizian P, Lacotte S, et al. Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data. Cancers (Basel). 2023;15(18):4574.</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Q</given-names></name></person-group><article-title>Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?</article-title><source>Front Immunol.</source><year>2023</year><volume>14</volume><fpage>1092401</fpage><?supplied-pmid 36875077?><pub-id pub-id-type="pmid">36875077</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Jiang J, Huang H, Chen R, Lin Y, Ling Q. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors? Front Immunol. 2023;14:1092401.<pub-id pub-id-type="pmid">36875077</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Gu Y, Xu S, Wang Z, Yang J, Zheng S, Wei Q, et al. When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road. Chin J Cancer Res. 2023;35(2):92&#x02013;107.</mixed-citation></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Demetris</surname><given-names>A</given-names></name><name><surname>Adams</surname><given-names>D</given-names></name><name><surname>Bellamy</surname><given-names>C</given-names></name><name><surname>Blakolmer</surname><given-names>K</given-names></name><name><surname>Clouston</surname><given-names>A</given-names></name><name><surname>Dhillon</surname><given-names>AP</given-names></name><etal/></person-group><article-title>Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection</article-title><source>An International Panel. Hepatology.</source><year>2000</year><volume>31</volume><issue>3</issue><fpage>792</fpage><lpage>9</lpage><?supplied-pmid 10706577?><pub-id pub-id-type="pmid">10706577</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel Hepatology. 2000;31(3):792&#x02013;9.<pub-id pub-id-type="pmid">10706577</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Lucey MR, Terrault N, Ojo L, Hay JE, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3&#x02013;26.</mixed-citation></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><collab>EASL Clinical Practice Guidelines</collab></person-group><article-title>Liver transplantation</article-title><source>J Hepatol.</source><year>2016</year><volume>64</volume><issue>2</issue><fpage>433</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">26597456</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">EASL Clinical Practice Guidelines. Liver transplantation. J Hepatol. 2016;64(2):433&#x02013;85.<pub-id pub-id-type="pmid">26597456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Finn</surname><given-names>RS</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Ducreux</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>T-Y</given-names></name><etal/></person-group><article-title>Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</article-title><source>N Engl J Med.</source><year>2020</year><volume>382</volume><issue>20</issue><fpage>1894</fpage><lpage>905</lpage><?supplied-pmid 32402160?><pub-id pub-id-type="pmid">32402160</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382(20):1894&#x02013;905.<pub-id pub-id-type="pmid">32402160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>A-L</given-names></name><name><surname>Kaseb</surname><given-names>AO</given-names></name><name><surname>Kudo</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>HC</given-names></name><etal/></person-group><article-title>Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial</article-title><source>Lancet.</source><year>2023</year><volume>402</volume><issue>10415</issue><fpage>1835</fpage><lpage>47</lpage><?supplied-pmid 37871608?><pub-id pub-id-type="pmid">37871608</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Qin S, Chen M, Cheng A-L, Kaseb AO, Kudo M, Lee HC, et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10415):1835&#x02013;47.<pub-id pub-id-type="pmid">37871608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Lucey</surname><given-names>MR</given-names></name><name><surname>Furuya</surname><given-names>KN</given-names></name><name><surname>Foley</surname><given-names>DP</given-names></name></person-group><article-title>Liver Transplantation</article-title><source>N Engl J Med.</source><year>2023</year><volume>389</volume><issue>20</issue><fpage>1888</fpage><lpage>900</lpage><?supplied-pmid 37966287?><pub-id pub-id-type="pmid">37966287</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Lucey MR, Furuya KN, Foley DP. Liver Transplantation. N Engl J Med. 2023;389(20):1888&#x02013;900.<pub-id pub-id-type="pmid">37966287</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Kwong AJ, Kim WR, Lake JR, Schladt DP, Schnellinger EM, Gauntt K, et al. OPTN/SRTR 2022 Annual Data Report: Liver. Am J Transplant. 2024;24(2S1):S176-S265.</mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Levitsky J, Goldberg D, Smith AR, Mansfield SA, Gillespie BW, Merion RM, et al. Acute Rejection Increases Risk of Graft Failure and Death in Recent Liver Transplant Recipients. Clin Gastroenterol Hepatol. 2017;15(4):584&#x02013;593.e2.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Moeckli B, Wassmer C-H, El Hajji S, Kumar R, Rodrigues Ribeiro J, Tabrizian P, et al. Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study. Hepatology. 2025.</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study</article-title><source>Am J Transplant.</source><year>2024</year><volume>24</volume><issue>10</issue><fpage>1837</fpage><lpage>56</lpage><?supplied-pmid 38642712?><pub-id pub-id-type="pmid">38642712</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Guo Z, Liu Y, Ling Q, Xu L, Wang T, Zhu J, et al. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study. Am J Transplant. 2024;24(10):1837&#x02013;56.<pub-id pub-id-type="pmid">38642712</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2022;20(5):1142&#x02013;1150.e4.</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Kuo</surname><given-names>F-C</given-names></name><name><surname>Chen</surname><given-names>C-Y</given-names></name><name><surname>Lin</surname><given-names>N-C</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Hsia</surname><given-names>C-Y</given-names></name><name><surname>Loong</surname><given-names>C-C</given-names></name></person-group><article-title>Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab</article-title><source>Transplant Proc.</source><year>2023</year><volume>55</volume><issue>4</issue><fpage>878</fpage><lpage>83</lpage><?supplied-pmid 37127513?><pub-id pub-id-type="pmid">37127513</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kuo F-C, Chen C-Y, Lin N-C, Liu C, Hsia C-Y, Loong C-C. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab. Transplant Proc. 2023;55(4):878&#x02013;83.<pub-id pub-id-type="pmid">37127513</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Kahramangil D, Zarrinpar A, Sahin I. Immune checkpoint inhibitors in the posttransplant landscape of HCC: A systematic literature review. Liver Transpl. 2024.</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AW</given-names></name><name><surname>Vionnet</surname><given-names>J</given-names></name><name><surname>Sanchez-Fueyo</surname><given-names>A</given-names></name></person-group><article-title>Understanding, predicting and achieving liver transplant tolerance: from bench to bedside</article-title><source>Nat Rev Gastroenterol Hepatol.</source><year>2020</year><volume>17</volume><issue>12</issue><fpage>719</fpage><lpage>39</lpage><?supplied-pmid 32759983?><pub-id pub-id-type="pmid">32759983</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Thomson AW, Vionnet J, Sanchez-Fueyo A. Understanding, predicting and achieving liver transplant tolerance: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2020;17(12):719&#x02013;39.<pub-id pub-id-type="pmid">32759983</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Perez-Gutierrez</surname><given-names>A</given-names></name><name><surname>Nakao</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><name><surname>Camirand</surname><given-names>G</given-names></name><name><surname>Yoshida</surname><given-names>O</given-names></name><etal/></person-group><article-title>Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance</article-title><source>Hepatology.</source><year>2018</year><volume>67</volume><issue>4</issue><fpage>1499</fpage><lpage>515</lpage><?supplied-pmid 28921638?><pub-id pub-id-type="pmid">28921638</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Ono Y, Perez-Gutierrez A, Nakao T, Dai H, Camirand G, Yoshida O, et al. Graft-infiltrating PD-L1hi cross-dressed dendritic cells regulate antidonor T cell responses in mouse liver transplant tolerance. Hepatology. 2018;67(4):1499&#x02013;515.<pub-id pub-id-type="pmid">28921638</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AW</given-names></name><name><surname>Knolle</surname><given-names>PA</given-names></name></person-group><article-title>Antigen-presenting cell function in the tolerogenic liver environment</article-title><source>Nat Rev Immunol.</source><year>2010</year><volume>10</volume><issue>11</issue><fpage>753</fpage><lpage>66</lpage><?supplied-pmid 20972472?><pub-id pub-id-type="pmid">20972472</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Thomson AW, Knolle PA. Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol. 2010;10(11):753&#x02013;66.<pub-id pub-id-type="pmid">20972472</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>X</given-names></name></person-group><article-title>Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future</article-title><source>J Clin Invest.</source><year>2015</year><volume>125</volume><issue>9</issue><fpage>3384</fpage><lpage>91</lpage><?supplied-pmid 26325035?><pub-id pub-id-type="pmid">26325035</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest. 2015;125(9):3384&#x02013;91.<pub-id pub-id-type="pmid">26325035</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Latchman</surname><given-names>Y</given-names></name><name><surname>Wood</surname><given-names>CR</given-names></name><name><surname>Chernova</surname><given-names>T</given-names></name><name><surname>Chaudhary</surname><given-names>D</given-names></name><name><surname>Borde</surname><given-names>M</given-names></name><name><surname>Chernova</surname><given-names>I</given-names></name><etal/></person-group><article-title>PD-L2 is a second ligand for PD-1 and inhibits T cell activation</article-title><source>Nat Immunol.</source><year>2001</year><volume>2</volume><issue>3</issue><fpage>261</fpage><lpage>8</lpage><?supplied-pmid 11224527?><pub-id pub-id-type="pmid">11224527</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261&#x02013;8.<pub-id pub-id-type="pmid">11224527</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Keir</surname><given-names>ME</given-names></name><name><surname>Butte</surname><given-names>MJ</given-names></name><name><surname>Freeman</surname><given-names>GJ</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>PD-1 and its ligands in tolerance and immunity</article-title><source>Annu Rev Immunol.</source><year>2008</year><volume>26</volume><fpage>677</fpage><lpage>704</lpage><?supplied-pmid 18173375?><pub-id pub-id-type="pmid">18173375</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677&#x02013;704.<pub-id pub-id-type="pmid">18173375</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Tian</surname><given-names>W</given-names></name></person-group><article-title>How to select IgG subclasses in developing anti-tumor therapeutic antibodies</article-title><source>J Hematol Oncol.</source><year>2020</year><volume>13</volume><issue>1</issue><fpage>45</fpage><?supplied-pmid 32370812?><pub-id pub-id-type="pmid">32370812</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Yu J, Song Y, Tian W. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. J Hematol Oncol. 2020;13(1):45.<pub-id pub-id-type="pmid">32370812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Qi</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Guan</surname><given-names>X</given-names></name><etal/></person-group><article-title>Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><issue>7</issue><fpage>1008</fpage><lpage>19</lpage><?supplied-pmid 31021376?><pub-id pub-id-type="pmid">31021376</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008&#x02013;19.<pub-id pub-id-type="pmid">31021376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Kueht</surname><given-names>ML</given-names></name><name><surname>Cotton</surname><given-names>RT</given-names></name><name><surname>Galvan</surname><given-names>NTN</given-names></name><name><surname>O'Mahony</surname><given-names>CA</given-names></name><name><surname>Goss</surname><given-names>JA</given-names></name><name><surname>Rana</surname><given-names>A</given-names></name></person-group><article-title>Profiling immunologic risk for acute rejection in liver transplantation: Recipient age is an important risk factor</article-title><source>Transpl Immunol.</source><year>2016</year><volume>38</volume><fpage>44</fpage><lpage>9</lpage><?supplied-pmid 27423762?><pub-id pub-id-type="pmid">27423762</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kueht ML, Cotton RT, Galvan NTN, O&#x02019;Mahony CA, Goss JA, Rana A. Profiling immunologic risk for acute rejection in liver transplantation: Recipient age is an important risk factor. Transpl Immunol. 2016;38:44&#x02013;9.<pub-id pub-id-type="pmid">27423762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Wu</surname><given-names>TJ</given-names></name><name><surname>Wu</surname><given-names>TH</given-names></name><name><surname>Lee</surname><given-names>CF</given-names></name><name><surname>Chou</surname><given-names>HS</given-names></name><name><surname>Chan</surname><given-names>KM</given-names></name><etal/></person-group><article-title>The risk factors to predict acute rejection in liver transplantation</article-title><source>Transplant Proc.</source><year>2012</year><volume>44</volume><issue>2</issue><fpage>526</fpage><lpage>8</lpage><?supplied-pmid 22410062?><pub-id pub-id-type="pmid">22410062</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wang YC, Wu TJ, Wu TH, Lee CF, Chou HS, Chan KM, et al. The risk factors to predict acute rejection in liver transplantation. Transplant Proc. 2012;44(2):526&#x02013;8.<pub-id pub-id-type="pmid">22410062</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>De Simone</surname><given-names>P</given-names></name><name><surname>Battistella</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>Q</given-names></name><name><surname>Ducci</surname><given-names>J</given-names></name><name><surname>D'Arcangelo</surname><given-names>F</given-names></name><name><surname>Marchetti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Immunosuppression for older liver transplant recipients</article-title><source>Transplant Rev (Orlando).</source><year>2024</year><volume>38</volume><issue>1</issue><fpage>100817</fpage><?supplied-pmid 38128152?><pub-id pub-id-type="pmid">38128152</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">De Simone P, Battistella S, Lai Q, Ducci J, D&#x02019;Arcangelo F, Marchetti P, et al. Immunosuppression for older liver transplant recipients. Transplant Rev (Orlando). 2024;38(1): 100817.<pub-id pub-id-type="pmid">38128152</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>